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ABSTRACT 
GENETIC ASSOCIATIONS WITH BORDERLINE PERSONALITY 
 
DISORDER AND RELATED TRAITS AND BEHAVIORS 
 
by Casey Roy Guillot 
August 2012 
Borderline personality disorder (BPD) and related traits and behaviors have been 
linked to a number of neurotransmitter systems, including serotonin, norepinephrine, 
GABA, and dopamine. Because three human single-nucleotide polymorphisms (SNPs), 
COMT rs4680, GABRA2 rs279871, and SNCA rs356195, have been linked to the above-
mentioned neurotransmitter systems, they may be associated with BPD and related traits 
and behaviors. The purpose of the current study is to examine associations of COMT 
rs4680, GABRA2 rs279871, and SNCA rs356195 with both categorical and continuous 
measures of BPD and with continuous measures of impulse control and self-harm in a 
nonclinical sample. Healthy volunteers were categorized into genotypic and allelic 
groups, and then those groups were compared in order to determine if certain genotypes 
and alleles are associated with specific categorical and continuous outcomes. COMT 
rs4680 was the only SNP related to both categorically and continuously measured BPD 
as well as to impulse control and self-harm scores. However, results with COMT rs4680 
often were suggestive of heterosis, which presents difficulty in explaining. In regard to 
the other SNPs, GABRA2 rs279871 was related to BPD, impulse control, and self-harm 
scores, whereas SNCA rs356195 was only related to the former two. All three SNPs  
yielded some gender-specific results, which may be explained by gender differences in  
 
ii 
one or more of the following: COMT activity, steroid hormone and neurosteroid levels, 
neurosteroid effects, regional brain structure, and DA and alpha-synuclein systems. In 
conclusion, it appears that COMT, GABRA2, and SNCA may influence the development 
of BPD and related traits and behaviors. 
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CHAPTER I 
INTRODUCTION 
 According to the revised 4
th
 edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2000), biological 
relatives of individuals with borderline personality disorder (BPD) are at increased risk of 
being diagnosed with BPD, and impulsivity and self-harm (including non-suicidal self-
injurious behavior and suicidal behavior) are both prominent features of BPD. Looking 
beyond the DSM-IV-TR, impulsivity has been prospectively associated with suicidal 
behavior (Mann et al., 2009; Yen et al., 2004) and with poorer long-term outcomes in 
BPD patients (Links, Mitton, & Steiner, 1990), and the early emergence of impulsivity is 
suspected of playing a major role in the development of BPD (Crowell, Beauchaine, & 
Linehan, 2009). Furthermore, BPD, impulsivity, non-suicidal self-injury (NSSI), and 
suicidal behavior all have been shown to be moderately heritable, with heritability 
estimates typically ranging from about 30% to 60% (Durrett, 2006; Mann et al., 2009), 
and a recent large-scale twin-family study has indicated that a common genetic factor 
accounts for a significant portion of the genetic variance in BPD and impulsivity/self-
harm (Distel et al., 2010). In summary, BPD, impulsivity, and self-harm are hereditarily 
influenced and appear to be related both developmentally and genetically. 
 Notably, a DSM-IV-TR diagnosis of BPD is categorical. In other words, an 
individual meeting certain DSM-IV-TR criteria is classified as having BPD, whereas an 
individual not meeting certain DSM-IV-TR criteria is classified as not having BPD. From 
this perspective, BPD is a dichotomous variable: Each person either has or does not have 
BPD at a specific point in time. Alternatively, BPD can be trichotomized, whereby 
2 
 
individuals are classified as having a clinical BPD diagnosis (e.g., a DSM-IV-TR 
diagnosis of BPD), a subclinical BPD diagnosis (i.e., falling one criterion short of a 
clinical diagnosis of BPD), or no BPD diagnosis, or BPD even can be dichotomized 
differently, such that individuals are classified as having a clinical/subclinical diagnosis 
of BPD (i.e., having either a clinical or subclinical diagnosis of BPD) or no diagnosis of 
BPD. Regardless if BPD is trichotomized or dichotomized in one way or another, it still 
remains a categorical variable. Importantly, however, BPD can also be conceptualized 
dimensionally. In other words, the number of BPD symptoms present in a particular 
individual can be measured, and then that individual can be classified according to his or 
her degree of BPD symptoms. From this perspective, BPD is a continuous variable: Each 
person has a certain level of BPD symptoms at a specific point in time. Thus, BPD can be 
measured both categorically and continuously. 
Although BPD traditionally has been conceptualized as a categorical diagnosis, 
the dimensional conceptualization of BPD has become increasingly relevant in recent 
decades. Taxometric analyses have indicated that BPD is optimally measured as a 
continuous variable (Edens, Marcus, & Ruiz, 2008; Trull, Widiger, & Guthrie, 1990). In 
nonclinical samples, BPD symptoms have been associated with alcohol and drug use 
disorders (Trull, Waudby, & Sher, 2004), and BPD features have been shown to predict 
future alcohol-related problems (Stepp, Trull, & Sher, 2005). Similarly, BPD has been 
shown to be one of the most commonly diagnosed personality disorders in samples of 
substance abusers (Grant et al., 2008, 2004; Sutker & Allain, 2001), and a diagnosis of 
BPD also has been shown to predict future onsets of substance use disorders (Walter et 
al., 2009). Given the advantages of measuring BPD continuously instead of categorically 
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and also that symptoms and features of BPD have been related to negative outcomes 
similar to that of a diagnosis of BPD, it is important to search for genetic associations 
with BPD measured both categorically and continuously. 
Genetic Associations with BPD and Related Traits and Behaviors 
BPD and related traits and behaviors have been linked to a number of 
neurotransmitter systems, including serotonin (5-HT), norepinephrine (NE), gamma-
aminobutyric acid (GABA), and dopamine (DA): Serotonergic dysfunction has been 
associated with BPD, impulsivity, NSSI, and suicidal behavior (Gurvits, Koenigsberg, & 
Siever, 2000; Krakowski, 2003; Lester, 1995; Mann, 2002); excessive noradrenergic 
activity has been implicated in heightened reactivity to stress and has been associated 
with risk taking, impulsivity, and irritability (Gurvits et al., 2000; Morilak et al., 2005; 
Swann, Birnbaum, Jagar, Dougherty, & Moeller, 2005); certain GABA agonists (e.g., 
valproate and carbamazepine) have been used to improve mood lability and impulsivity 
in patients with BPD (Gurvits et al., 2000; Siever & Weinstein, 2009); and DA-receptor 
antagonists (e.g., haloperidol and flupenthixol) have been shown to decrease impulsivity 
and suicidal behavior in patients with BPD (Friedel, 2004).  
Given their relationship with the above-mentioned neurotransmitter systems, the 
following three human single-nucleotide polymorphisms (SNPs) may be associated with 
BPD and related traits and behaviors: (1) COMT rs4680 (catechol-O-methyltransferase 
gene, reference SNP 4680), also known as COMT Val158Met; (2) GABRA2 rs279871 
(gamma-aminobutyric acid A receptor subunit alpha-2 gene, reference SNP 279871); and 
(3) SNCA rs356195 (alpha-synuclein gene, reference SNP 356195). To elaborate, 
catechol-O-methyltransferase (COMT) is an enzyme responsible for the inactivation of 
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catecholamines, including DA and NE, via catalysis of their methylation (Lachman et al., 
1996; Mannisto & Kaakkola, 1999; Weinshilboum, Otterness, & Szumlanski, 1999), and 
genotypic variation in COMT rs4680 has been shown to affect COMT activity in several 
organs, including the brain (Chen et al., 2004; Lachman et al., 1996; Mannisto & 
Kaakkola, 1999; Weinshilboum et al., 1999). Although GABA-A receptor -2 subunits 
(which are encoded by GABRA2) mostly have been related to anxiety (Dixon, Rosahl, & 
Stephens, 2008; Lehner et al., 2010; Low et al., 2000), they are distributed in brain 
regions involved in the regulation of emotion (e.g., prefrontal cortex, amygdala, and 
hippocampus) (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al., 2010; Low et al., 
2000; Tian, Chen, Cross, & Edenberg, 2005) and therefore may be involved in other 
emotional responses and emotionally driven behaviors, such as depression 
(Vollenweider, Smith, Keist, & Rudolph, 2011) and impulsive actions motivated by 
negative affective states (Villafuerte et al., 2011). Finally, -synuclein (which is encoded 
by SNCA) has been shown to affect DA biosynthesis and release (Venda, Cragg, 
Buchman, & Wade-Martins, 2010) and may modulate DA, 5-HT, and NE transporter 
activity (Venda et al., 2010; Wersinger, Jeannotte, & Sidhu, 2006; Wersinger, Rusnak, & 
Sidhu, 2006; however, also see Senior et al., 2008). 
As stated previously, BPD, impulsivity, and self-harm are all moderately heritable 
and appear to share genetic influence. In the following subsections, I have provided direct 
and indirect evidence regarding the association of COMT rs4680, GABRA2 rs279871, 
and SNCA rs356195 with BPD, impulsivity, and self-harm, although evidence pertaining 
to the latter two SNPs apparently is completely lacking in some areas at this time. 
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BPD and Symptoms of BPD 
 Of the three SNPs reviewed here, only COMT rs4680 has been examined in 
relation to BPD and symptoms of BPD. One study found a relationship between COMT 
rs4680 and BPD (Tadic et al., 2009), whereas another study failed to find a relationship 
between COMT rs4680 and symptoms of BPD (Nemoda et al., 2010).  
Impulsivity and Impulsivity-Related Traits and Behaviors 
 Several studies have searched for a relationship between COMT rs4680 and 
impulsivity or impulsivity-related traits (e.g., novelty seeking and sensation seeking), 
yielding mixed results (Benjamin et al., 2000; Chen et al., 2011; Colzato, van den 
Wildenberg, van der Does, & Hommel, 2010; Demetrovics et al., 2010; Drabant et al., 
2006; Forbes et al., 2009; Golimbet, Alfimova, Gritsenko, & Ebstein, 2007; Hashimoto et 
al., 2007; Hosak, Libiger, Cizek, Beranek, & Cermakova, 2006; Ishii et al., 2007; Kang, 
Song, Namkoong, & Kim, 2010; Kim, Kim, Kim, Lee, & Kim, 2006; Lang, Bajbouj, 
Sander, & Gallinat, 2007; Light et al., 2007; Paloyelis, Asherson, Mehta, Faraone, & 
Kuntsi, 2010; Reuter & Hennig, 2005; Strobel, Lesch, Jatzke, Paetzold, & Brocke, 2003; 
Tsai, Hong, Yu, & Chen, 2004; Zalsman et al., 2008). One study failed to reveal a 
relationship between GABRA2 rs279871 and novelty seeking (Dick, Agrawal, et al., 
2006); however, CSF GABA levels and cortical GABA concentrations have both been 
related to impulsivity in humans (Boy et al., 2011; Lee, Petty, & Coccaro, 2009), and 
GABA-A agonists have been shown to increase impulsive responding in rodents (Le et 
al., 2008; Oliver, Ripley, & Stephens, 2009; Thiebot, Le Bihan, Soubrie, & Simon, 1985) 
and impair inhibitory control in humans (Acheson, Reynolds, Richards, & de Wit, 2006; 
Deakin, Aitken, Dowson, Robbins, & Sahakian, 2004; Fillmore, Rush, Kelly, & Hays, 
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2001), which is consistent with the possibility that impulsivity is regulated in part by 
GABA-A receptor -2 subunits. Although SNCA rs356195 has not been specifically 
related to impulsivity or impulsivity-related traits, -synuclein expression in the striatum 
has been shown to influence stimulant-induced locomotion in rodents (Abeliovich et al., 
2000; Boyer & Dreyer, 2007), which is a behavior associated with impulsive responding 
in rats (Dellu-Hagedorn, 2006). 
Self-Harm 
 All of the self-harm research involving the currently reviewed SNPs has been 
conducted in relation to COMT rs4680. Several studies have reported a relationship 
between COMT rs4680 and suicidal behavior (Baud et al., 2007; Nolan et al., 2000; Ono, 
Shirakawa, Nushida, Ueno, & Maeda, 2004; Rujescu, Giegling, Gietl, Hartmann, & 
Moller, 2003), but a recent meta-analysis and a simultaneously conducted study both 
failed to reveal a relationship between COMT rs4680 and suicidal behavior (Calati et al., 
2011). In addition, one study failed to find a relationship between COMT rs4680 and 
self-harm scores (Silberschmidt & Sponheim, 2008). Although GABRA2 rs279871 has 
not been specifically related to self-harm, participants administered the benzodiazepine 
diazepam, a GABA-A agonist (Atack, 2005), have displayed increased self-aggression 
(Berman, Jones, & McCloskey, 2005), and personality-disordered individuals with a 
history of suicide attempts have displayed higher CSF GABA levels than personality-
disordered individuals without a history of suicide attempts (Lee et al., 2009). 
Purpose of the Current Study 
 Most of the above-reviewed behavioral genetic studies involved the separate 
examination of one of the following two outcomes: (1) potential differences in genotypic 
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and allelic frequencies between groups of individuals with and without BPD, or (2) 
potential differences in mean scores on dimensional measures of BPD or related traits 
and behaviors between genotypic and allelic groups. The purpose of the current study is 
to examine associations of COMT rs4680, GABRA2 rs279871, and SNCA rs356195 
with both categorical and continuous measures of BPD and also with continuous 
measures of impulse control and self-harm in a nonclinical sample. Therefore, in the 
current study healthy volunteers were categorized into genotypic and allelic groups, and 
then those groups were compared in order to determine if certain genotypes and alleles 
are associated with specific categorical and continuous outcomes. Because several studies 
have indicated that COMT and GABRA2 genotypic/allelic group differences in 
impulsivity or self-harm may be gender-specific (Baud et al., 2007; Chen et al., 2011; 
Golimbet et al., 2007; Lang et al., 2007; Nolan et al., 2000; Ono et al., 2004; Villafuerte 
et al., 2011), separate analyses for men and women were also conducted. 
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CHAPTER II 
METHOD 
Participants 
A total of 222 participants were included in genotype testing. One participant was 
excluded because of difficulty in genotyping across multiple polymorphisms, and two 
participants were excluded because of only having genotyping data. In order to limit the 
potentially confounding effects of population stratification, only participants who self-
identified as Caucasian were retained. Of the remaining 145 participants, 5 were 
excluded because of lacking self-report data, leaving a total sample of 140 (77 male and 
63 female) healthy Caucasian volunteers between the ages of 21 and 55 (M = 26.14; SD = 
7.75). Participants were recruited from the university and community through fliers, 
university-based e-mail announcements, and newspaper and online advertisements 
requesting volunteers for a paid study ($10 per hour) on the effects of alcohol on motor 
skills. All potential participants were screened by telephone interview and were excluded 
if they reported that they had previously participated in alcohol-related research, had not 
experienced alcohol intoxication during the past few years, were currently taking 
medication with which alcohol should not be consumed, had ever experienced a 
significant medical problem that was directly attributed to alcohol use, had ever been 
diagnosed with schizophrenia or bipolar disorder, had experienced a depressive or 
anxiety disorder in the past six months, had a psychological problem for which they were 
currently engaged in treatment, or had a significant medical condition (e.g., heart, liver, 
or kidney problems, diabetes, neurological disorder, or hypertension). Participants were 
told that on the day of alcohol administration (which is not part of the current study but 
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usually occurred within a few days to a week of it) they would be screened for alcohol 
and drugs and would not be allowed to proceed if they had alcohol or any recreational 
drugs in their system. During the phone screen, a cut-off score of nine on the Alcohol 
Use Disorders Identification Test (AUDIT) was used to exclude potential problem 
drinkers (58-92% sensitivity; Barry & Fleming, 1993; Fleming, Barry, & MacDonald, 
1991; Kokotailo et al., 2004; Selin, 2006). In order to further limit the presence of 
problem drinking, non-excluded individuals scoring 7 or higher on the AUDIT (68-94% 
sensitivity; Barry & Fleming, 1993; Fleming et al., 1991; Kokotailo et al., 2004; Selin, 
2006) were also administered the Short Michigan Alcoholism Screening Test (SMAST) 
and were excluded if they scored 3 or higher (67-100% sensitivity; Nanakorn, Fukuda, 
Ogimoto, Tangseree, & Treethiptikhun, 2000; Selzer, Vinokur, & van Rooijen, 1975; 
Zung, 1984). Finally, weight and height were recorded for all participants, and 
participants with a body mass index of 35 or greater (indicative of severe obesity) (World 
Health Organization, 2003) were also excluded. The current study used data that was 
collected as part of a larger research project primarily devoted to the examination of the 
effects of alcohol on self-aggressive behavior. The overall study was approved by The 
University of Southern Mississippi Human Subjects Protection Review Committee. 
Measures 
 Impulse Control Measures 
 Barratt Impulsiveness Scale, Version 11 (BIS-11). The 30-item BIS-11 was used 
to measure trait impulsivity (Patton, Stanford, & Barratt, 1995). Items are answered on a 
4-point frequency scale (Rarely/Never, Occasionally, Often, Almost Always/Always), and 
each item response is scored from 1 (indicative of the least impulsive response) to 4 
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(indicative of the most impulsive response). BIS-11 total scores have been shown to be 
higher in prison inmates in comparison to psychiatric and substance-abuse patients and 
lower in college undergraduates in comparison to prison inmates and both groups of 
patients (Patton et al., 1995).  In the initial BIS-11 study, Cronbach’s alpha for the total 
score ranged from .79 to .83 (Patton et al., 1995). 
Self-Control Scale (SCS). The SCS was used to measure ability to self-regulate 
(Tangney, Baumeister, & Boone, 2004). The instrument consists of 36 items answered on 
a 5-point scale, with 1 representing not at all like me and 5 representing very much like 
me. Each item response is scored from 1 (indicative of the least amount of self-control) to 
5 (indicative of the greatest amount of self-control). Higher SCS scores have been shown 
to predict greater emotional stability and less binge eating, alcohol abuse, and self- and 
other-directed aggression (Tangney et al., 2004). In the initial SCS study, Cronbach’s 
alpha and test-retest reliability both were .89 (Tangney et al., 2004).  
Self-Harm Measures 
Life History of Aggression (LHA). The 2-item LHA Self-Directed Aggression 
subscale was used to assess history of self-aggression (Coccaro, Berman, & Kavoussi, 
1997). The first item pertains to past frequency of self-injurious behavior, and the second 
item pertains to past frequency of suicide attempts. Items are answered on a 6-point scale 
ranging from 0 (never happened) to 5 (happened so many times I couldn’t give a 
number). LHA Self-Directed Aggression scores have been shown to be higher in 
participants diagnosed with BPD in comparison to healthy participants (Coccaro et al., 
1997). In the initial LHA study, Cronbach’s alpha and test-retest reliability for the LHA 
Self-Directed Aggression subscale were .48 and .97, respectively (Coccaro et al., 1997). 
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 Self-Harm Inventory (SHI). The SHI was developed to assess history of 
intentional self-harm and to screen for BPD (Sansone, Wiederman, & Sansone, 1998). 
The instrument consists of 22 yes/no items, and yes and no responses are scored 1 and 0, 
respectively, with higher scores representing a more extensive history of intentional self-
harm and a greater likelihood of BPD. Cronbach’s alpha for the SHI has ranged from .80 
to .90 (Sansone, Butler, Dakroub, & Pole, 2006; Sansone, Reddington, Sky, & 
Wiederman, 2007; Sansone, Songer, & Sellbom, 2006). 
Measures of BPD, Impulse Control, and Self-Harm 
 Schedule for Nonadaptive and Adaptive Personality-2 (SNAP-2).  The SNAP-2 
was used to assess personality traits and personality-disorder symptoms and to diagnose 
DSM-IV personality disorders (Clark, Simms, Wu, & Casillas, in press). The SNAP-2 
consists of 390 items comprising 12 trait scales, 3 temperament scales, and 12 diagnostic 
scales. The diagnostic scales can be used to assess personality disorders dimensionally 
and diagnostically based on number of symptoms and DSM-IV diagnostic criteria met, 
respectively. The following four SNAP-2 scales were included in the current study:  
Borderline, Impulsivity, Disinhibition, and Self-Harm. One of the Self-Harm subscales, 
Suicide Proneness, was also included. Items are answered using a true/false format, and 
item responses are scored 0 or 1, with 1 being indicative of a higher level of a trait or the 
presence of a personality-disorder symptom and/or diagnostic criterion. In normative 
samples, Cronbach’s alpha for SNAP-2 Impulsivity, Disinhibition, Self-Harm, and 
Suicide Proneness ranged from .74 to .84, and test-retest reliability ranged from .76 to .93 
(Clark et al., in press). 
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Procedure 
Written informed consent was obtained from participants prior to participation. 
All measures were self-report instruments. The SNAP-2 was administered in 
computerized form (Clark & Simms, 2004). All other measures were administered as 
online questionnaires. 
Blood was collected for genotyping using the following procedure: Latex gloves 
were placed on both of the researcher’s hands. The participant’s index finger was 
swabbed with an alcohol swipe on the side opposite the nail in order to reduce the chance 
of local infection. An automatic fingerstick lancet device was then used to puncture the 
soft side of the participant’s fingertip, slightly removed from the center. After blood from 
the participant’s finger had accumulated into a tiny ball (which was eased with slight 
pressure to the surrounding tissue if necessary), the blood was spotted onto 3MM 
chromatography paper (Whatman, Inc., Florham Park, NJ) which was located inside a 
rectangular collection form. This was repeated until three approximately 1.25 cm spots of 
blood were created on the paper. The collection form was then labeled with the date, the 
participant’s initials and coded number, and the name of the research assistant who 
collected the blood sample. The sample was allowed a few minutes to dry before being 
placed in a small plastic zip bag, which was then placed in a hanging folder inside a metal 
file cabinet until all samples were ready to be mailed for genotype determination. Gloves, 
alcohol swipes, and lancets were disposed of in a biohazard container. 
Genotyping 
 Dried blood samples were analyzed at the Alcohol Research Center at Indiana 
University. DNA was isolated using the HotSHOT method, which is a fast and cost-
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effective way to isolate PCR quality genomic DNA (Truett et al., 2000). In this method, 
TaqMan probes are used for allelic discrimination (Applied BioSystems, Inc., Foster 
City, CA). The allelic discrimination assay is a multiplexed (one primer pair/two probes 
per reaction), end-point (data is collected at the end of the PCR process) assay. Each 
assay mix contains two different TaqMan probes labeled with VIC or FAM fluorescent 
reporter dye which bind preferentially to one of the alleles. The genotype of each sample 
is determined by the fluorescence levels of the reporter dyes and is clustered on a graph 
with other samples of the same genotype. Each reaction contains 5 ul of 2X TaqMan 
Universal PCR Mastermix, No AmpErase UNG, 3.75 ul of water, 0.25ul of 40X Assay 
Mix, and 1ul of DNA sample. Eight or eleven controls are included on each 96-well 
plate: 2 no template controls, 2 or 3 heterozygous samples, and 2 or 3 of each of the 
homozygous samples. Because genotyping is done by endpoint reading, thermocycling is 
carried out in MJ Research PTC-200 thermocyclers. The PCR products are then analyzed 
in an ABI PRISM® 7300 Sequence Detection System (SDS) instrument. SDS Software 
1.3.1 converts the raw data to pure dye components and plots the results of the allelic 
discrimination on a scatter plot of Allele X versus Allele Y; each genotype appears on the 
graph as a cluster of points. 
Data Analysis 
Data analysis was conducted primarily with SPSS Statistics 17.0 for Windows. 
Alpha was set at .05 for all analyses unless otherwise noted. The SNAP-2 Borderline 
scale was analyzed both continuously and categorically, and the remaining continuous 
measures were grouped conceptually as follows: impulse control (BIS-11, SCS, SNAP-2 
Impulsivity, and SNAP-2 Disinhibition) and self-harm (LHA Self-Directed Aggression, 
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SHI, SNAP-2 Self-Harm, and SNAP-2 Suicide Proneness). Two-tailed Fisher’s exact 
tests were used to evaluate relationships between genotypic/allelic groups and categorical 
measures (i.e., diagnoses of clinical and clinical/subclinical BPD). For one-way analyses 
of variance, Levene’s test was used to test for violations of homogeneity of variance. 
Although Keppel (1991, p. 127) recommended increasing the power of a similar test of 
equality of variances (the Brown-Forsythe test) by setting the value of  at .25, the 
sensitivity of Levene’s test has been called into question particularly for small cell sizes 
(Lee, Katz, & Restori, 2010; Nordstokke & Zumbo, 2007; Zimmerman, 2004); therefore, 
 was set at .35 for comparisons involving any cell sizes of less than 15 and at .25 for 
comparisons involving only cell sizes of 15 or more, thus increasing the power of the test 
both generally and specifically for small cell sizes. The ANOVA F-test was used to test 
for group differences on continuous measures when there was no evidence of unequal 
variances; otherwise, the Welch test was used. For genotypic group comparisons, a post 
hoc multiple comparisons procedure was employed if the omnibus test was significant or 
nearly significant: Tukey’s test was used when there was no evidence of unequal 
variances; otherwise, the Games-Howell test was used. Because multiple comparisons 
procedures such as Tukey’s test and the Games-Howell test do not require a preliminary 
test in order to be valid (Myers & Well, 2003, pp. 248-252; Ryan, 1959), the significance 
or non-significance of the post hoc multiple comparisons procedure overrode that of the 
omnibus test when there was a discrepancy in significance between the two tests. 
Although not as worrisome as the effects of variance heterogeneity, the ANOVA F-test 
has displayed some sensitivity to non-normality when variances are equal, particularly 
when group sizes are unequal (Games, 1983; Harwell, Rubinstein, Hayes, & Olds, 1992; 
15 
 
Levine & Dunlap, 1982; Milligan, Wong, & Thompson, 1987). Also, the Welch test has 
displayed sensitivity to departures from normality when variances are unequal (Clinch & 
Keselman, 1982; Harwell et al., 1992; Lix, Keselman, & Keselman, 1996). However, 
non-normality under each of the preceding conditions rarely has been shown to increase 
the Type I error rate higher than approximately twice the nominal level relative to 
ANOVA (Harwell et al., 1992; Levine & Dunlap, 1982; Lix et al., 1996; Milligan et al., 
1987) and the Welch test (Clinch & Keselman, 1982; Harwell et al., 1992; Lix et al., 
1996). Therefore, the Shapiro-Wilk test was used to test for non-normality when an 
ANOVA or Welch test was significant or nearly significant at the standard  level (p < 
.10), and if the Shapiro-Wilk test was significant, then  for the corresponding ANOVA 
or Welch test (and if applicable the subsequent multiple comparisons procedure) was 
adjusted to .025 in order to correct for potential Type I error inflation due to non-
normality (a strategy suggested by Keppel, 1991, p. 97). Given the frequent violations of 
homogeneity of variance found in behavioral science data sets (Keselman et al., 1998), 
using the Mann-Whitney and Kruskal-Wallis tests when distributions were non-normal 
was not desirable because the Type I error rates of such nonparametric tests are often 
substantially more inflated by concurrent violations of normality and homogeneity of 
variance in comparison to parametric tests (Cribbie & Keselman, 2003; Zimmerman, 
1998, 2003). In order to avoid reduced power for detecting relationships, Bonferroni 
corrections were not performed, and instead the effect sizes of significant findings were 
emphasized, which is a practice that has been recommended in whole or in part by a 
number of researchers (Garamszegi, 2006; Kirk, 2001; Moran, 2003; Nakagawa, 2004; 
O’Keefe, 2003; Perneger, 1998; Stoehr, 1999). If SPSS yielded p = .000 for a parametric 
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analysis, then a more precise value for p was computed using the p-value calculator 
located at http://www.graphpad.com/quickcalcs/pvalue1.cfm (GraphPad Software, 2012). 
Cohen’s ds for pairwise comparisons of means were computed using the effect size 
calculator retrieved from http://mason.gmu.edu/~dwilsonb/downloads/ES_Calculator.xls 
(Lipsey & Wilson, 2001). Risk ratios (also known as relative risks) for binary categorical 
relationships were computed using the 2 x 2 contingency table calculator located at 
http://faculty.vassar.edu/lowry/odds2x2.html (Lowry, 2012). In regard to allelic group 
comparisons, each homozygote group was compared to the combined group of 
heterozygotes and opposing homozygotes (i.e., the combined group of individuals 
sharing at least one allele) for all SNPs, which is a widely held practice in the literature. 
However, the heterozygote group was compared to the combined group of homozygotes 
only for COMT rs4680 and GABRA2 rs279871 because the homozygote groups were 
comparable in size for both of those SNPs, whereas for SNCA rs356195 the common 
homozygote group, CC participants, was about 7 times larger than the rare homozygote 
group, TT participants; consequently, the mean scores for the combined group of SNCA 
homozygotes (CC/TT participants) would have been severely biased in the direction of 
the mean scores for the common homozygotes. 
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CHAPTER III 
RESULTS 
Genotype Frequencies and Group Demographics 
Genotype frequencies and percent distributions for COMT rs4680, GABRA2 
rs279871, and SNCA rs356195 in the total sample are shown in Table 1. None of the 
genotypic frequency distributions deviated significantly from expected Hardy-Weinberg 
equilibrium, as ascertained with the Hardy-Weinberg equilibrium calculator located at 
http://www.oege.org/software/hwe-mr-calc.shtml (Rodriguez, Gaunt, & Day, 2009).  
Table 1 
 
Genotype Frequencies and Percent Distributions in the Total Sample 
 
 
               Genotype Frequency (%)   
         ___________________________________________________ 
 
        SNP        Genotype 1                       Genotype 2                       Genotype 3 
 
 
COMT rs4680               AA         AG              GG 
 
 
           41 (29.3)               74 (52.9)                    25 (17.9) 
 
 
GABRA2 rs279871  AA                    AG                         GG 
 
 
           40 (28.6)               72 (51.4)                    28 (20.0) 
 
 
SNCA rs356195  CC                     CT               TT 
 
 
           78 (55.7)               51 (36.4)                     11 (7.9) 
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Demographics for each of the genotypic groups in the total sample are shown in 
Table 2. Genotypic groups for each of the three polymorphisms did not differ 
significantly in respect to gender, age, and years of education. 
Table 2 
 
Demographics for Genotypic Groups in the Total Sample 
 
 
          M (SD)   
         ___________________________________________________ 
 
        SNP        Group 1                              Group 2                             Group 3 
 
 
COMT rs4680           AA        AG              GG 
 
 
  Male/Female ratio        28/13      35/39           14/11 
 
  Age     27.10 (8.95)            25.97 (7.12)      25.08 (7.61) 
 
  Education (years)   16.72 (2.20)            16.44 (2.14)      16.68 (1.46) 
 
 
GABRA2 rs279871         AA                   AG                         GG 
 
 
  Male/Female ratio        27/13      38/34           12/16 
 
  Age     26.88 (9.06)            25.34 (6.70)      27.15 (8.30) 
 
  Education (years)   17.13 (1.81)            16.28 (2.09)      16.48 (2.14) 
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Table 2 (continued). 
 
 
          M (SD)   
         ___________________________________________________ 
 
        SNP        Group 1                              Group 2                             Group 3 
 
 
SNCA rs356195          CC                    CT                          TT 
 
 
  Male/Female ratio        44/34       28/23       5/6 
 
  Age     26.10 (7.85)            26.74 (8.05)      23.64 (5.39) 
 
  Education (years)   16.61 (2.29)            16.51 (1.75)      16.55 (1.51) 
 
 
COMT Rs4680 
SNAP-2 Borderline scale 
 Although an omnibus Welch test indicated that the differences in Borderline 
scores between COMT genotypic groups in the total sample were only nearly significant 
(adjusted  = .025), Welch statistic (2, 61.94) = 3.62, p = .032, 
2
 = .041, the post hoc 
Games-Howell test revealed significantly higher Borderline scores (p = .022, d = .47) in 
AG participants (M = 7.96, SD = 5.19) in comparison to AA participants (M = 5.74, SD = 
3.44). Moreover, COMT allelic group comparisons revealed significantly lower 
Borderline scores (adjusted  = .025) in AA participants (M = 5.74, SD = 3.44) relative to 
GG/AG participants (M = 7.66, SD = 5.11), Welch statistic (1, 99.28) = 6.42, p = .013, d 
= .41, and significantly higher Borderline scores (adjusted  = .025) in AG participants 
(M = 7.96, 5.19) relative to AA/GG participants (M = 6.14, SD = 4.05), Welch statistic 
(1, 134.06) = 5.29, p = .023, d = .39. Analysis by gender failed to reveal any significant 
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differences in Borderline scores between COMT genotypic and allelic groups. To 
summarize results for COMT thus far, AG participants displayed higher Borderline 
scores, and AA participants displayed lower Borderline scores. 
 In regard to the relationship between COMT group membership and BPD 
diagnosis, a Fisher’s exact test revealed a significant relationship between COMT 
zygosity and clinical/subclinical BPD in the total sample (p = .038,  = .186, RR = 6.81), 
such that COMT heterozygotes (AG participants) had a greater risk of being diagnosed 
with clinical/subclinical BPD than COMT homozygotes (AA/GG participants). This 
relationship was also significant in men (Fisher’s exact test, p = .043,  = .254) but not in 
women (Fisher’s exact test, p = .643,  = .105). No other categorical relationships were 
significant in the total sample or by gender. To summarize results for COMT in relation 
to the SNAP-2 Borderline scale, AA participants reported less symptoms of BPD, and 
COMT heterozygosis was related to dimensionally and diagnostically measured BPD, 
such that COMT heterozygotes reported more symptoms of BPD and had a greater risk of 
being diagnosed with clinical/subclinical BPD. 
Impulse Control 
 No significant differences in impulse control were detected between COMT 
genotypic and allelic groups in the total sample or in men. In women, however, an 
omnibus Welch test indicated that the differences in SNAP-2 Disinhibition scores 
between COMT genotypic groups were nearly significant (adjusted  = .025), Welch 
statistic (2, 26.92) = 4.06, p = .029, 
2
 = .082, and the post hoc Games-Howell test 
revealed significantly higher SNAP-2 Disinhibition scores (p = .019, d = .72) in AG 
participants (M = 11.10, SD = 6.72) in comparison to GG participants (M = 6.64, SD = 
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3.70). Also in women, COMT allelic group comparisons revealed significantly lower 
SNAP-2 Disinhibition scores (adjusted  = .025) in GG participants (M = 6.64, SD = 
3.70) relative to AA/AG participants (M = 10.63, SD = 6.22), Welch statistic (1, 24.15) = 
7.97, p = .009, d = .68, nearly significantly higher BIS-11 scores in AG participants (M = 
67.49, SD = 14.26) relative to AA/GG participants (M = 62.09, SD = 7.08), Welch 
statistic (1, 58.69) = 3.95, p = .052, d = .45, significantly lower SCS scores (indicative of 
greater impulsivity) in AG participants (M = 118.44, SD = 20.42) relative to AA/GG 
participants (M = 131.09, SD = 18.31), F (1, 60) = 5.98, p = .017, d = .64, and 
significantly higher SNAP-2 Disinhibition scores (adjusted  = .025) in AG participants 
(M = 11.10, SD = 6.72) relative to AA/GG participants (M = 7.91, SD = 4.01), Welch 
statistic (1, 59.97) = 5.48, p = .023, d = .54. To summarize results for COMT in regard to 
impulse control, group differences were found only in women, with female GG 
participants reporting less impulsivity on one measure and female AG participants 
reporting greater impulsivity across multiple measures. 
Self-Harm 
 In the total sample, COMT genotype was significantly related (adjusted  = .025) 
to LHA Self-Directed Aggression scores, Welch statistic (2, 74.50) = 7.74, p = .001, 
2
 = 
.037, and SNAP-2 Self-Harm scores, Welch statistic (2, 72.31) = 4.50, p = .014, 
2
 = 
.044, and the post hoc Games-Howell tests revealed significantly higher LHA Self-
Directed Aggression scores (p = .001, d = .51) in AG participants (M = .59, SD = 1.24) in 
comparison to GG participants (M = .04, SD = .20) and significantly higher SNAP-2 Self-
Harm scores (p = .01, d = .54) in AG participants (M = 1.74, SD = 2.05) in comparison to 
GG participants (M = .72, SD = 1.21). COMT allelic group comparisons further revealed 
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significantly lower LHA Self-Directed Aggression scores (adjusted  = .025) in GG 
participants (M = .04, SD = .20) relative to AA/AG participants (M = .50, SD = 1.20), 
Welch statistic (1, 133.38) = 14.89, p = .0002, d = .42, significantly lower SNAP-2 Self-
Harm scores (adjusted  = .025) in GG participants (M = .72, SD = 1.21) relative to 
AA/AG participants (M = 1.58, SD = 1.95), Welch statistic (1, 56.02) = 8.01, p = .006, d 
= .47, nearly significantly higher SNAP-2 Self-Harm scores (adjusted  = .025) in AG 
participants (M = 1.74, SD = 2.05) relative to AA/GG participants (M = 1.05, SD = 1.55), 
Welch statistic (1, 133.15) = 5.09, p = .026, d = .38, and significantly higher SNAP-2 
Suicide Proneness scores (adjusted  = .025) in AG participants (M = .86, SD = 1.34) 
relative to AA/GG participants (M = .43, SD = .86), Welch statistic (1, 125.83) = 5.32, p 
= .023, d = .38. To summarize the self-harm results for COMT in the total sample thus 
far, GG and AG participants displayed lower and higher scores, respectively, across 
multiple measures.  
No significant differences in self-harm were detected between COMT genotypic 
and allelic groups in women. In men, no significant differences in self-harm were 
detected between COMT genotypic groups, but COMT allelic group comparisons 
revealed significantly lower Suicide Proneness scores (adjusted  = .025) in AA 
participants (M = .27, SD = .53) relative to GG/AG participants (M = .82, SD = 1.27), 
Welch statistic (1, 70.32) = 6.83, p = .011, d = .51. Thus, COMT group differences in 
self-harm in the total sample did not appear to be primarily related to either gender, 
although one gender-specific difference was found in men. 
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COMT rs4680 Results Summary 
Of all COMT genotypes, AG was most consistently associated with BPD and 
related traits and behaviors: COMT heterozygotes displayed higher SNAP-2 Borderline 
scores, greater risk of being diagnosed with clinical/subclinical BPD, and higher LHA 
Self-Directed Aggression, SNAP-2 Self-Harm, and SNAP-2 Suicide Proneness scores. In 
addition, female heterozygotes displayed lower SCS scores (indicative of greater 
impulsivity) and higher BIS-11 and SNAP-2 Disinhibition scores. In contrast to 
heterozygotes, AA participants displayed lower SNAP-2 Borderline scores, and male AA 
participants displayed lower SNAP-2 Suicide Proneness scores. Also, GG participants 
displayed lower LHA Self-Directed Aggression and SNAP-2 Self-Harm scores, and 
female GG participants displayed lower SNAP-2 Disinhibition scores. Mean scores for 
COMT genotypic and allelic groups in the total sample and by gender are shown in 
Tables 3-8, and frequencies for COMT zygosity by BPD clinical/subclinical diagnosis are 
shown in Table 9. 
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Table 3 
 
Scores for COMT rs4680 Genotypic Groups in the Total Sample 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 41)                         (n = 74)                          (n = 25) 
 
 
SNAP-2 BDL
a
        5.74 (3.44)*       7.96 (5.19)*         6.76 (4.85) 
 
BIS-11
b
          62.60 (11.22)     65.35 (12.08)       62.72 (7.91) 
 
SCS
b
                          124.68 (21.49)               121.61 (19.47)               127.04 (18.12) 
 
SNAP-2 IMP
a
    5.18 (3.58)       5.85 (4.02)          5.36 (3.59) 
 
SNAP-2 DIS
a
  10.13 (5.83)     11.61 (6.08)          9.40 (4.75) 
 
LHA SIB
b
      .33 (1.12)         .59 (1.24)**           .04 (.20)** 
 
SHI
c
     1.90 (3.05)       3.03 (3.24)          2.40 (1.98) 
 
SNAP-2 SH
a
    1.26 (1.72)       1.74 (2.05)*           .72 (1.21)* 
 
SNAP-2 SP
a
                    .39 (.82)         .86 (1.34)            .48 (.92) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SIB = Self-Injurious Behavior; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aThree AA participants failed to complete the SNAP-2. bOne AA participant failed to complete the BIS-11, SCS, and LHA Self- 
 
Injurious Behavior subscale. cOne AA and one AG participant failed to complete the SHI. 
 
*different at p < .05; **different at p < .01 
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Table 4 
 
Scores for COMT rs4680 Allelic Groups in the Total Sample 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 41)    (n = 99) 
 
SNAP-2 BDL
a
                 5.74 (3.44)*            7.66 (5.11)* 
 
BIS-11
b
                 62.60 (11.22)          64.69 (11.19) 
 
SCS
b 
                                124.68 (21.49)        122.98 (19.19) 
 
SNAP-2 IMP
a 
           5.18 (3.58)            5.73 (3.91) 
 
SNAP-2 DIS
a
         10.13 (5.83)          11.05 (5.83) 
 
LHA SIB
b
             .33 (1.12)   .45 (1.10) 
 
SHI
c
            1.90 (3.05)            2.87 (2.97) 
 
SNAP-2 SH
a
            1.26 (1.72)            1.48 (1.92) 
 
SNAP-2 SP
a
               .39 (.82)   .77 (1.25) 
 
 
     GG    AA/AG 
 
             (n = 25)    (n = 115) 
 
SNAP-2 BDL
a
                6.76 (4.85)            7.21 (4.77) 
 
BIS-11
b
                62.72 (7.91)          64.39 (11.81) 
 
SCS
b 
                               127.04 (18.12)        122.68 (20.16) 
 
SNAP-2 IMP
a
          5.36 (3.59)            5.63 (3.87) 
 
SNAP-2 DIS
a
          9.40 (4.75)          11.11 (6.01) 
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Table 4 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG 
 
             (n = 25)    (n = 115) 
 
LHA SIB
b
            .04 (.20)***              .50 (1.20)*** 
 
SHI
c
           2.40 (1.98)            2.63 (3.21) 
 
SNAP-2 SH
a
             .72 (1.21)**            1.58 (1.95)** 
 
SNAP-2 SP
a
              .48 (.92)   .71 (1.21) 
 
 
     AG    AA/GG 
 
             (n = 74)    (n = 66) 
 
SNAP-2 BDL
a
                7.96 (5.19)*             6.14 (4.05)* 
 
BIS-11
b
                65.35 (12.08)           62.65 (10.01) 
 
SCS
b 
                               121.61 (19.47)         125.58 (20.15) 
 
SNAP-2 IMP
a
          5.85 (4.02)             5.25 (3.56) 
 
SNAP-2 DIS
a
        11.61 (6.08)             9.84 (5.40) 
 
LHA SIB
b
            .59 (1.24)   .22 (.89) 
 
SHI
c
           3.03 (3.24)            2.09 (2.68) 
 
SNAP-2 SH
a
          1.74 (2.05)
†
            1.05 (1.55)
† 
 
SNAP-2 SP
a
             .86 (1.34)*   .43 (.86)* 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SIB = Self-Injurious Behavior; SH = Self-Harm; SP = Suicide  
 
Proneness. 
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Table 4 (continued). 
 
 
aThree AA participants failed to complete the SNAP-2. bOne AA participant failed to complete the BIS-11, SCS, and LHA Self- 
 
Injurious Behavior subscale. cOne AA and one AG participant failed to complete the SHI. 
 
†nearly significantly different; *different at p < .05; **different at p < .01; ***different at p < .001 
 
Table 5 
 
Scores for COMT rs4680 Genotypic Groups in Men 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 28)                         (n = 35)                          (n = 14) 
 
 
SNAP-2 BDL
a
        5.65 (3.29)       7.66 (5.44)          8.07 (4.34) 
 
BIS-11          63.04 (12.23)     62.97 (8.65)        62.79 (9.85) 
 
SCS
  
                          122.07 (22.49)  125.14 (17.98)     123.57 (17.22) 
 
SNAP-2 IMP
a  
   5.08 (4.01)      5.31 (3.24)          5.93 (3.85) 
 
SNAP-2 DIS
a
  10.62 (6.49)    12.17 (5.33)        11.57 (4.43) 
 
LHA SDA      .14 (.53)        .40 (1.01)            .07 (.27) 
 
SHI     1.64 (2.88)      2.77 (3.27)          2.50 (2.07) 
 
SNAP-2 SH
a
    1.27 (1.76)      1.69 (2.13)            .79 (1.31) 
 
SNAP-2 SP
a
                    .27 (.53)        .89 (1.32)            .64 (1.15) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aTwo male AA participants failed to complete the SNAP-2. 
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Table 6 
 
Scores for COMT rs4680 Allelic Groups in Men 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 28)    (n = 49) 
 
SNAP-2 BDL
a
                 5.65 (3.29)            7.78 (5.11) 
 
BIS-11                 63.04 (12.23)          62.92 (8.90) 
 
SCS
 
                                 122.07 (22.49)        124.69 (17.60) 
 
SNAP-2 IMP
a
          5.08 (4.01)            5.49 (3.40) 
 
SNAP-2 DIS
a
        10.62 (6.49)          12.00 (5.05) 
 
LHA SDA            .14 (.53)   .31 (.87) 
 
SHI           1.64 (2.88)            2.69 (2.96) 
 
SNAP-2 SH
a
           1.27 (1.76)            1.43 (1.96) 
 
SNAP-2 SP
a
              .27 (.53)*   .82 (1.27)* 
 
 
     GG    AA/AG 
 
             (n = 14)    (n = 63) 
 
SNAP-2 BDL
a
                8.07 (4.34)            6.80 (4.72) 
 
BIS-11                62.79 (9.85)          63.00 (10.30) 
 
SCS
 
                                123.57 (17.22)        123.78 (20.00) 
 
SNAP-2 IMP
a
          5.93 (3.85)            5.21 (3.56) 
 
SNAP-2 DIS
a   
       11.57 (4.43)          11.51 (5.86) 
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Table 6 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG 
 
             (n = 14)    (n = 63) 
 
LHA SDA            .07 (.27)   .29 (.83) 
 
SHI           2.50 (2.07)            2.27 (3.13) 
 
SNAP-2 SH
a
             .79 (1.31)            1.51 (1.97) 
 
SNAP-2 SP
a
              .64 (1.15)   .62 (1.10) 
 
 
     AG    AA/GG 
 
             (n = 35)    (n = 42) 
 
SNAP-2 BDL
a
                7.66 (5.44)             6.50 (3.82) 
 
BIS-11                62.97 (8.65)           62.95 (11.37) 
 
SCS                                 125.14 (17.98)         122.57 (20.68) 
 
SNAP-2 IMP
a
           5.31 (3.24)             5.38 (3.93) 
 
SNAP-2 DIS
a   
       12.17 (5.33)           10.95 (5.81) 
 
LHA SDA            .40 (1.01)    .12 (.45) 
 
SHI           2.77 (3.27)             1.93 (2.65) 
 
SNAP-2 SH
a
          1.69 (2.13)             1.10 (1.61) 
 
SNAP-2 SP
a
             .89 (1.32)    .40 (.81) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aTwo male AA participants failed to complete the SNAP-2. 
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Table 6 (continued). 
 
 
*different at p < .05 
 
Table 7 
 
Scores for COMT rs4680 Genotypic Groups in Women 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 13)                         (n = 39)                          (n = 11) 
 
 
SNAP-2 BDL
a
        5.92 (3.90)       8.23 (5.00)          5.09 (5.15) 
 
BIS-11
a
          61.58 (8.83)     67.49 (14.26)       62.64 (4.88) 
 
SCS
a
                          130.75 (18.41)   118.44 (20.42)     131.45 (19.09) 
 
SNAP-2 IMP
a
    5.42 (2.54)       6.33 (4.60)          4.64 (3.26) 
 
SNAP-2 DIS
a
    9.08 (4.08)     11.10 (6.72)*         6.64 (3.70)* 
 
LHA SDA
a
      .75 (1.87)         .77 (1.40)            .00 (.00) 
 
SHI
b
     2.50 (3.45)       3.26 (3.24)          2.27 (1.95) 
 
SNAP-2 SH
a
    1.25 (1.71)       1.79 (2.02)            .64 (1.12) 
 
SNAP-2 SP
a
                    .67 (1.23)         .85 (1.37)            .27 (.47) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne female AA participant failed to complete the SNAP-2, BIS-11, SCS, and LHA Self-Directed Aggression. bOne female AA  
 
participant and one female AG participant failed to complete the SHI. 
 
*different at p < .05 
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Table 8 
 
Scores for COMT rs4680 Allelic Groups in Women 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 13)    (n = 50) 
 
SNAP-2 BDL
a
                 5.92 (3.90)            7.54 (5.15) 
 
BIS-11
a
                 61.58 (8.83)          66.42 (12.91) 
 
SCS
a
                                130.75 (18.41)        121.30 (20.68) 
 
SNAP-2 IMP
a
          5.42 (2.54)            5.96 (4.37) 
 
SNAP-2 DIS
a
          9.08 (4.08)          10.12 (6.42) 
 
LHA SDA
a
            .75 (1.87)   .60 (1.28) 
 
SHI
b
           2.50 (3.45)            3.04 (3.01) 
 
SNAP-2 SH
a
           1.25 (1.71)            1.54 (1.91) 
 
SNAP-2 SP
a
              .67 (1.23)   .72 (1.25) 
 
 
     GG    AA/AG  
 
             (n = 11)    (n = 52) 
 
SNAP-2 BDL
a
                5.09 (5.15)            7.69 (4.83) 
 
BIS-11
a
                62.64 (4.88)          66.10 (13.34) 
 
SCS
a 
                               131.45 (19.09)        121.33 (20.48) 
 
SNAP-2 IMP
a
          4.64 (3.26)            6.12 (4.20) 
 
SNAP-2 DIS
a
          6.64 (3.70)**          10.63 (6.22)** 
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Table 8 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG  
 
             (n = 11)    (n = 52) 
 
LHA SDA
a
            .00 (.00)   .76 (1.51) 
 
SHI
b
           2.27 (1.95)            3.08 (3.27) 
 
SNAP-2 SH
a
             .64 (1.12)            1.67 (1.95) 
 
SNAP-2 SP
a
              .27 (.47)   .80 (1.33) 
 
 
     AG    AA/GG 
 
             (n = 39)    (n = 24) 
 
SNAP-2 BDL
a
                8.23 (5.00)             5.52 (4.45) 
 
BIS-11
a
                67.49 (14.26)
†
           62.09 (7.08)
† 
 
SCS
a
                               118.44 (20.42)*         131.09 (18.31)* 
 
SNAP-2 IMP
a
         6.33 (4.60)             5.04 (2.87) 
 
SNAP-2 DIS
a
       11.10 (6.72)*             7.91 (4.01)* 
 
LHA SDA
a
           .77 (1.40)   .39 (1.37) 
 
SHI
b
          3.26 (3.24)            2.39 (2.78) 
 
SNAP-2 SH
a
         1.79 (2.02)   .96 (1.46) 
 
SNAP-2 SP
a
            .85 (1.37)   .48 (.95) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
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Table 8 (continued). 
 
 
aOne female AA participant failed to complete the SNAP-2, BIS-11, SCS, and LHA Self-Directed Aggression. bOne female AA  
 
participant and one female AG participant failed to complete the SHI. 
 
†nearly significantly different; *different at p < .05; **different at p < .01 
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Table 9 
 
COMT rs4680 Zygosity by SNAP-2 BPD Clinical/Subclinical Diagnosis (Frequencies) 
 
 
                 Total Sample 
 
                                                 No diagnosis      Diagnosis 
                
                
                        
                                       AG 
 
 
 
 
                                AA/GG 
 
 
                       Relationship between COMT 
    zygosity and diagnosis  
(p = .038,  = .186, OR = 7.52) 
 
 
        Men                Women 
 
 No diagnosis    Diagnosis           No diagnosis      Diagnosis 
31 4 
 
                 AG 
 
 
             AA/AG 
35 4 
40 0 22 1 
Relationship between COMT          Relationship between COMT 
zygosity and diagnosis          zygosity and diagnosis 
(p = .043,  = .254)           (p = .643,  = .105) 
 
 
Note. Risk ratios by gender were not included because one of the cell counts for men was equal to zero. 
 
 
 
66 8 
62 1 
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GABRA2 Rs279871 
SNAP-2 Borderline scale 
 No significant differences in Borderline scores were detected between GABRA2 
genotypic and allelic groups in the total sample or in women. In men, no significant 
differences in Borderline scores were detected between GABRA2 genotypic groups, but 
GABRA2 allelic group comparisons revealed significantly lower Borderline scores 
(adjusted  = .025) in GG participants (M = 4.50, SD = 3.71) relative to AA/AG 
participants (M = 7.52, SD = 4.68), Welch statistic (1, 18.39) = 6.13, p = .023, d = .66. 
No significant relationships between GABRA2 group membership and BPD diagnosis 
were found in the total sample or by gender. To summarize results for GABRA2 thus far, 
male GG participants reported more symptoms of BPD. 
Impulse Control 
 No significant differences in impulse control were detected between GABRA2 
genotypic and allelic groups in the total sample or in men. Although an omnibus Welch 
test indicated that the differences between BIS-11 scores between GABRA2 genotypic 
groups in women were only nearly significant, Welch statistic (2, 27.79) = 3.29, p = .052, 
2
 = .076, the post hoc Games-Howell test revealed significantly higher BIS-11 scores (p 
= .037, d = .60) in AG participants (M = 68.53, SD = 12.71) in comparison to GG 
participants (M = 61.87, SD = 5.62). GABRA2 allelic group comparisons in women also 
revealed significantly higher BIS-11 scores in AG participants (M = 68.53, SD = 12.71) 
relative to AA/GG participants (M = 61.79, SD = 10.92), F (1, 60) = 4.90, p = .031, d = 
.56. To summarize results for GABRA2 in regard to impulse control, group differences 
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were found only in women, with female AG participants reporting greater impulsivity 
and female GG participants reporting less impulsivity on one measure. 
Self-Harm 
 No significant differences in self-harm were detected between GABRA2 
genotypic and allelic groups in the total sample or in women. In men, no significant 
differences in self-harm were detected between GABRA2 genotypic groups, but 
GABRA2 allelic group comparisons revealed significantly lower SHI scores (adjusted  
= .025) in GG participants (M = 1.08, SD = 1.31) relative to AA/AG participants (M = 
2.54, SD = 3.12), Welch statistic (1, 38.78) = 7.22, p = .011, d = .50, and nearly 
significantly lower SNAP-2 Suicide Proneness scores (adjusted  = .025) in GG 
participants (M = .25, SD = .45) relative to AA/AG participants (M = .70, SD = 1.17), 
Welch statistic (1, 44.3) = 5.17, p = .028,  d = .41. To summarize results for GABRA2 in 
regard to self-harm, male GG participants reported less self-harm across multiple 
measures. 
GABRA2 rs279871 Results Summary 
 Of all GABRA2 genotypes, GG was most consistently associated with BPD and 
related traits and behaviors: Male GG participants displayed lower SNAP-2 Borderline, 
SHI, and SNAP-2 Suicide Proneness scores, and female GG participants displayed lower 
BIS-11 scores. Also, female AG participants displayed higher BIS-11 scores. Notably, all 
differences between GABRA2 genotypic and allelic groups were gender-specific. Mean 
scores for GABRA2 genotypic and allelic groups in the total sample and by gender are 
shown in Tables 10-15. 
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Table 10 
 
Scores for GABRA2 rs279871 Genotypic Groups in the Total Sample 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 40)                         (n = 72)                          (n = 28) 
 
 
SNAP-2 BDL
a
        7.26 (4.78)       7.59 (4.94)          5.79 (4.20) 
 
BIS-11
b
          62.83 (12.28)     66.00 (10.71)       60.85 (10.15) 
 
SCS
b
                          122.43 (21.35)   122.61 (18.53)     127.30 (21.09) 
 
SNAP-2 IMP
a
    5.00 (3.33)       6.17 (4.13)          4.89 (3.50) 
 
SNAP-2 DIS
a
  10.67 (5.35)     11.51 (6.04)          9.18 (5.76) 
 
LHA SDA
b
      .23 (.66)         .58 (1.32)            .26 (.94) 
 
SHI
c
     2.93 (3.56)       2.72 (2.96)          1.74 (2.11) 
 
SNAP-2 SH
a
    1.67 (2.11)       1.20 (1.54)          1.64 (2.23) 
 
SNAP-2 SP
a
                    .74 (1.16)         .59 (1.06)            .75 (1.40) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne AA participant and two AG participants failed to complete the SNAP-2. bOne GG participant failed to complete the BIS-11,  
 
SCS, and LHA Self-Directed Aggression. cOne AG and one GG participant failed to complete the SHI. 
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Table 11 
 
Scores for GABRA2 rs279871 Allelic Groups in the Total Sample 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 40)   (n = 100) 
 
SNAP-2 BDL
a
                 7.26 (4.78)            7.07 (4.79) 
 
BIS-11
b
                 62.83 (12.28)          64.60 (10.76) 
 
SCS
b 
                                122.43 (21.35)        123.89 (19.26) 
 
SNAP-2 IMP
a 
           5.00 (3.33)            5.81 (3.98) 
 
SNAP-2 DIS
a
         10.67 (5.35)          10.85 (6.03) 
 
LHA SDA
b
             .23 (.66)   .49 (1.23) 
 
SHI
c
            2.93 (3.56)            2.45 (2.77) 
 
SNAP-2 SH
a
            1.67 (2.11)            1.33 (1.76) 
 
SNAP-2 SP
a
               .74 (1.16)   .63 (1.16) 
 
 
     GG    AA/AG 
 
             (n = 28)    (n = 112) 
 
SNAP-2 BDL
a
                5.79 (4.20)            7.47 (4.86) 
 
BIS-11
b
                60.85 (10.15)          64.87 (11.34) 
 
SCS
b 
                               127.30 (21.09)        122.54 (19.49) 
 
SNAP-2 IMP
a
          4.89 (3.50)            5.75 (3.89) 
 
SNAP-2 DIS
a
          9.18 (5.76)          11.21 (5.79) 
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Table 11 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG 
 
             (n = 28)    (n = 112) 
 
LHA SDA
b
            .26 (.94)   .46 (1.14) 
 
SHI
c
           1.74 (2.11)            2.79 (3.17) 
 
SNAP-2 SH
a
           1.64 (2.23)            1.37 (1.77) 
 
SNAP-2 SP
a
              .75 (1.40)   .64 (1.09) 
 
 
     AG    AA/GG 
 
             (n = 72)    (n = 68) 
 
SNAP-2 BDL
a
                7.59 (4.94)             6.64 (4.58) 
 
BIS-11
b
                66.00 (10.71)           62.03 (11.43) 
 
SCS
b 
                               122.61 (18.53)         124.39 (21.22) 
 
SNAP-2 IMP
a
          6.17 (4.13)             4.96 (3.38) 
 
SNAP-2 DIS
a
        11.51 (6.04)           10.04 (5.53) 
 
LHA SDA
b
            .58 (1.32)   .24 (.78) 
 
SHI
c
           2.72 (2.96)            2.45 (3.09) 
 
SNAP-2 SH
a
          1.20 (1.54)            1.66 (2.14) 
 
SNAP-2 SP
a
             .59 (1.06)   .75 (1.26) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
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Table 11 (continued). 
 
 
aOne AA participant and two AG participants failed to complete the SNAP-2. bOne GG participant failed to complete the BIS-11,  
 
SCS, and LHA Self-Directed Aggression. cOne AG and one GG participant failed to complete the SHI. 
 
Table 12 
 
Scores for GABRA2 rs279871 Genotypic Groups in Men 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 27)                         (n = 38)                          (n = 12) 
 
 
SNAP-2 BDL
a
        7.31 (4.98)       7.68 (4.52)          4.50 (3.71) 
  
BIS-11          63.37 (10.89)     63.74 (8.05)        59.58 (14.15) 
 
SCS
 
                          122.19 (19.00)   123.74 (17.03)     127.25 (27.48) 
 
SNAP-2 IMP
a
    5.04 (3.19)       5.59 (3.59)          5.25 (4.62) 
 
SNAP-2 DIS
a
  10.77 (5.00)     12.49 (5.65)        10.17 (6.52) 
 
LHA SDA      .15 (.46)         .39 (1.00)            .00 (.00) 
 
SHI     2.96 (3.89)       2.24 (2.45)          1.08 (1.31) 
 
SNAP-2 SH
a
    1.62 (2.19)       1.16 (1.52)          1.50 (2.24) 
 
SNAP-2 SP
a
                    .85 (1.32)         .59 (1.07)            .25 (.45) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne male AA participant and one male AG participant failed to complete the SNAP-2. 
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Table 13 
 
Scores for GABRA2 rs279871 Allelic Groups in Men 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 27)   (n = 50) 
 
SNAP-2 BDL
a
                 7.31 (4.98)            6.90 (4.51) 
 
BIS-11                 63.37 (10.89)          62.74 (9.85) 
 
SCS
 
                                 122.19 (19.00)        124.58 (19.77) 
 
SNAP-2 IMP
a 
           5.04 (3.19)            5.51 (3.82) 
 
SNAP-2 DIS
a
         10.77 (5.00)          11.92 (5.89) 
 
LHA SDA             .15 (.46)   .30 (.89) 
 
SHI            2.96 (3.89)            1.96 (2.28) 
 
SNAP-2 SH
a
            1.62 (2.19)            1.24 (1.70) 
 
SNAP-2 SP
a
               .85 (1.32)   .51 (.96) 
 
 
     GG    AA/AG 
 
             (n = 12)    (n = 65) 
 
SNAP-2 BDL
a
                4.50 (3.71)*            7.52 (4.68)* 
 
BIS-11                59.58 (14.15)          63.58 (9.25) 
 
SCS
 
                                127.25 (27.48)        123.09 (17.75) 
 
SNAP-2 IMP
a
          5.25 (4.62)            5.37 (3.42) 
 
SNAP-2 DIS
a
        10.17 (6.52)          11.78 (5.42) 
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Table 13 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG 
 
             (n = 12)    (n = 65) 
 
LHA SDA            .00 (.00)   .29 (.82) 
 
SHI           1.08 (1.31)*            2.54 (3.12)* 
 
SNAP-2 SH
a
           1.50 (2.24)            1.35 (1.82) 
 
SNAP-2 SP
a
              .25 (.45)
†
   .70 (1.17)
† 
 
 
     AG    AA/GG 
 
             (n = 38)    (n = 39) 
 
SNAP-2 BDL
a
                7.68 (4.52)            6.42 (4.75) 
 
BIS-11                63.74 (8.05)          62.21 (11.92) 
 
SCS
 
                                123.74 (17.03)        123.74 (21.71) 
 
SNAP-2 IMP
a
          5.59 (3.59)            5.11 (3.64) 
 
SNAP-2 DIS
a
        12.49 (5.65)          10.58 (5.44) 
 
LHA SDA            .39 (1.00)   .10 (.38) 
 
SHI           2.24 (2.45)            2.38 (3.41) 
 
SNAP-2 SH
a
          1.16 (1.52)            1.58 (2.18) 
 
SNAP-2 SP
a
             .59 (1.07)   .66 (1.15) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne male AA participant and one male AG participant failed to complete the SNAP-2. 
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Table 13 (continued). 
 
 
†nearly significantly different; *different at p < .05 
 
Table 14 
 
Scores for GABRA2 rs279871 Genotypic Groups in Women 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            AA                                AG                                 GG 
 
Measure                           (n = 13)                         (n = 34)                          (n = 16) 
 
 
SNAP-2 BDL
a
        7.15 (4.56)       7.48 (5.44)          6.75 (4.41) 
 
BIS-11
b
          61.69 (15.21)     68.53 (12.71)*       61.87 (5.62)* 
 
SCS
b
                          122.92 (26.42)   121.35 (20.25)     127.33 (15.24) 
 
SNAP-2 IMP
a
    4.92 (3.73)       6.82 (4.62)          4.63 (2.50) 
 
SNAP-2 DIS
a
  10.46 (6.21)     10.42 (6.36)          8.44 (5.22) 
 
LHA SDA
b
      .38 (.96)         .79 (1.59)            .47 (1.25) 
 
SHI
c
     2.85 (2.88)       3.27 (3.40)          2.27 (2.49) 
 
SNAP-2 SH
a
    1.77 (2.01)       1.24 (1.58)          1.75 (2.30) 
 
SNAP-2 SP
a
                    .54 (.78)         .58 (1.06)          1.13 (1.75) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne female AG participant failed to complete the SNAP-2. bOne female GG participant failed to complete the BIS-11, SCS, and LHA  
 
Self-Directed Aggression. cOne female AG participant and one female GG participant failed to complete the SHI. 
 
*different at p < .05 
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Table 15 
 
Scores for GABRA2 rs279871 Allelic Groups in Women 
 
 
Measure   M (SD)    M (SD) 
 
 
      AA    GG/AG 
 
              (n = 13)   (n = 50) 
 
SNAP-2 BDL
a
                 7.15 (4.56)            7.24 (5.09) 
 
BIS-11
b
                 61.69 (15.21)          66.49 (11.40) 
 
SCS
b 
                                122.92 (26.42)        123.18 (18.91) 
 
SNAP-2 IMP
a 
           4.92 (3.73)            6.10 (4.16) 
 
SNAP-2 DIS
a
         10.46 (6.21)            9.78 (6.03) 
 
LHA SDA
b
             .38 (.96)   .69 (1.49) 
 
SHI
c
            2.85 (2.88)            2.96 (3.16) 
 
SNAP-2 SH
a
            1.77 (2.01)            1.41 (1.84) 
 
SNAP-2 SP
a
               .54 (.78)   .76 (1.33) 
 
 
     GG    AA/AG 
 
             (n = 16)    (n = 47) 
 
SNAP-2 BDL
a
                6.75 (4.41)            7.39 (5.16) 
 
BIS-11
b
                61.87 (5.62)          66.64 (13.63) 
 
SCS
b 
                               127.33 (15.24)        121.79 (21.84) 
 
SNAP-2 IMP
a
          4.63 (2.50)            6.28 (4.43) 
 
SNAP-2 DIS
a
          8.44 (5.22)          10.43 (6.25) 
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Table 15 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
     GG    AA/AG 
 
             (n = 16)    (n = 47) 
 
LHA SDA
b
            .47 (1.25)   .68 (1.45) 
 
SHI
c
           2.27 (2.49)            3.15 (3.24) 
 
SNAP-2 SH
a
           1.75 (2.30)            1.39 (1.71) 
 
SNAP-2 SP
a
            1.13 (1.75)   .57 (.98) 
 
 
     AG    AA/GG 
 
             (n = 34)    (n = 29) 
 
SNAP-2 BDL
a
                7.48 (5.44)            6.93 (4.40) 
 
BIS-11
b
                68.53 (12.71)*          61.79 (10.92)* 
 
SCS
b 
                               121.35 (20.25)        125.29 (20.88) 
 
SNAP-2 IMP
a
          6.82 (4.62)            4.76 (3.06) 
 
SNAP-2 DIS
a
        10.42 (6.36)            9.34 (5.67) 
 
LHA SDA
b
            .79 (1.59)   .43 (1.10) 
 
SHI
c
           3.27 (3.40)            2.54 (2.65) 
 
SNAP-2 SH
a
          1.24 (1.58)            1.76 (2.13) 
 
SNAP-2 SP
a
             .58 (1.06)   .86 (1.41) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
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Table 15 (continued). 
 
 
aOne female AG participant failed to complete the SNAP-2. bOne female GG participant failed to complete the BIS-11, SCS, and LHA  
 
Self-Directed Aggression. cOne female AG participant and one female GG participant failed to complete the SHI. 
 
*different at p < .05 
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SNCA Rs356195 
SNAP-2 Borderline scale 
 No significant differences in Borderline scores were detected between SNCA 
genotypic and allelic groups in the total sample or in men. In women, an omnibus Welch 
test indicated that SNCA genotype was significantly related (adjusted  = .025) to 
Borderline scores, Welch statistic (2, 13.30) = 6.13, p = .013, 
2
 = .172, but the post hoc 
Games-Howell test only revealed nearly significantly higher Borderline scores in TT 
participants (M = 13.33, SD = 4.59) in comparison to CC participants (M = 6.24, SD = 
3.61, p = .026, d = 1.89) and CT participants (M = 7.04, SD = 5.70, p = .045, d = 1.14). 
Consistent with previous findings, however, SNCA allelic group comparisons revealed 
significantly higher Borderline scores (adjusted  = .025) in female TT participants (M = 
13.33, SD = 4.59) relative to female CC/CT participants (M = 6.57, SD = 4.55), F (1, 60) 
= 11.94, p = .001, d = 1.48. No significant relationships between SNCA group 
membership and BPD diagnosis were found in the total sample or by gender. To 
summarize results for SNCA thus far, the only significant finding in relation to BPD was 
in women, with female TT participants reporting more symptoms of BPD. 
Impulse Control 
 In the total sample, no significant differences in impulse control were detected 
between SNCA genotypic groups, but SNCA allelic group comparisons revealed 
significantly higher BIS-11 scores in CT/TT participants (M = 66.39, SD = 12.30) 
relative to CC participants (M = 62.28, SD = 9.97), Welch statistic (1, 114.02) = 4.50, p = 
.036, d = .37, significantly lower SCS scores (indicative of greater impulsivity) in CT/TT 
participants (M = 119.28, SD = 20.11) relative to CC participants (M = 126.74, SD = 
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19.08), F (1, 137) = 5.00, p = .027, d = .38, nearly significantly higher SNAP-2 
Impulsivity scores (adjusted  = .025) in CT/TT participants (M = 6.38, SD = 4.39) 
relative to CC participants (M = 4.95, SD = 3.18), Welch statistic (1, 103.68) = 4.55, p = 
.035, d = .38, nearly significantly higher SNAP-2 Disinhibition scores (adjusted  = .025) 
in CT/TT participants (M = 11.97, SD = 6.20) relative to CC participants (M = 9.88, SD = 
5.38), Welch statistic (1, 117.16) = 4.27, p = .041, d = .36, and nearly significantly higher 
BIS-11 scores in TT participants (M = 70.18, SD = 12.97) relative to CC/CT participants 
(M = 63.56, SD = 10.94), F (1, 137) = 3.61, p = .060, d = .60. To summarize results for 
SNCA in the total sample, CT/TT participants reported greater impulsivity on all impulse 
control measures, and TT participants reported greater impulsivity on one measure. 
In men, no significant differences were detected between SNCA genotypic 
groups, but SNCA allelic group comparisons revealed significantly lower SCS scores 
(indicative of greater impulsivity) in CT/TT participants (M = 117.85, SD = 18.56) 
relative to CC participants (M = 128.16, SD = 19.05), F (1, 75) = 5.64, p = .020, d = .55. 
Similar to men, no significant differences in impulse control were detected between 
SNCA genotypic groups in women, but SNCA allelic group comparisons revealed nearly 
significantly higher BIS-11 scores in CT/TT participants (M = 68.75, SD = 13.55) 
relative to CC participants (M = 62.79, SD = 10.66), Welch statistic (1, 50.76) = 3.58, p = 
.064, d = .50. Thus, SNCA group differences in impulsivity in the total sample did not 
appear to be primarily related to either gender overall, although differences on certain 
measures appeared to be more gender-specific. 
 
 
49 
 
Self-Harm 
 No significant differences in self-harm were detected across SNCA genotypic and 
allelic groups in the total sample or by gender. 
SNCA rs356195 Results Summary 
Although not as clear as with the other two SNPs, a pattern for SNCA did emerge 
in regard to BPD and related traits and behaviors: Female TT participants displayed 
higher SNAP-2 Borderline scores, and participants possessing at least one T allele 
(CT/TT participants) reported greater impulsivity on all impulse control measures, with 
some evidence to suggest that possessing two T alleles may confer additional risk of 
greater impulsivity (higher BIS-11 scores in TT participants). Therefore, T seemed to be 
a risk allele for SNCA in relation to impulsivity generally and BPD symptoms 
specifically in women. Mean scores for SNCA genotypic and allelic groups in the total 
sample and by gender are shown in Tables 16-21. 
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Table 16 
 
Scores for SNCA rs356195 Genotypic Groups in the Total Sample 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            CC                                CT                                   TT 
 
Measure                           (n = 78)                         (n = 51)                          (n = 11) 
 
 
SNAP-2 BDL
a
        6.48 (4.19)       7.68 (5.14)          9.30 (6.45) 
 
BIS-11
b
          62.28 (9.97)     65.56 (12.13)       70.18 (12.97) 
 
SCS
b
                          126.74 (19.08)   121.04 (18.57)     111.27 (25.52) 
 
SNAP-2 IMP
a
    4.95 (3.18)       6.46 (4.50)          6.00 (4.03) 
 
SNAP-2 DIS
a
    9.88 (5.38)     11.90 (6.49)        12.30 (4.76) 
 
LHA SDA
b
      .40 (1.14)         .38 (1.03)            .73 (1.19) 
 
SHI
c
     2.31 (3.04)       2.94 (3.09)          3.00 (2.49) 
 
SNAP-2 SH
a
    1.22 (1.69)       1.52 (1.93)          2.50 (2.55) 
 
SNAP-2 SP
a
                    .62 (1.06)         .62 (1.21)          1.20 (1.55) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne CC, one CT, and one TT participant failed to complete the SNAP-2. bOne CT participant failed to complete the BIS-11, SCS,  
 
and LHA Self-Directed Aggression. cTwo CT participants failed to complete the SHI. 
 
 
 
 
 
 
 
 
 
51 
 
Table 17 
 
Scores for SNCA rs356195 Allelic Groups in the Total Sample 
 
 
Measure   M (SD)    M (SD) 
 
 
      CC      CT/TT 
 
              (n = 78)    (n = 62) 
 
SNAP-2 BDL
a
                 6.48 (4.19)            7.95 (5.35) 
 
BIS-11
b
                 62.28 (9.97)*          66.39 (12.30)* 
 
SCS
b 
                                126.74 (19.08)*        119.28 (20.11)* 
 
SNAP-2 IMP
a 
           4.95 (3.18)
†
            6.38 (4.39)
† 
 
SNAP-2 DIS
a
           9.88 (5.38)
†
          11.97 (6.20)
† 
 
LHA SDA
b
             .40 (1.14)   .44 (1.06) 
 
SHI
c
            2.31 (3.04)            2.95 (2.97) 
 
SNAP-2 SH
a
            1.22 (1.69)            1.68 (2.05) 
 
SNAP-2 SP
a
               .62 (1.06)   .72 (1.28) 
 
 
      TT     CC/CT 
 
             (n = 11)    (n = 129) 
 
SNAP-2 BDL
a
                9.30 (6.45)            6.95 (4.60) 
 
BIS-11
b
                70.18 (12.97)
†
          63.56 (10.94)
† 
 
SCS
b 
                               111.27 (25.52)        124.52 (19.01) 
 
SNAP-2 IMP
a
          6.00 (4.03)            5.54 (3.81) 
 
SNAP-2 DIS
a
        12.30 (4.76)          10.68 (5.90) 
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Table 17 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
      TT     CC/CT 
 
             (n = 11)    (n = 129) 
 
LHA SDA
b
            .73 (1.19)   .39 (1.10) 
 
SHI
c
           3.00 (2.49)            2.55 (3.06) 
 
SNAP-2 SH
a
           2.50 (2.55)            1.34 (1.79) 
 
SNAP-2 SP
a
            1.20 (1.55)   .62 (1.12) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne CC, one CT, and one TT participant failed to complete the SNAP-2. bOne CT participant failed to complete the BIS-11, SCS,  
 
and LHA Self-Directed Aggression. cTwo CT participants failed to complete the SHI. 
 
†nearly significantly different; *different at p < .05 
 
Table 18 
 
Scores for SNCA rs356195 Genotypic Groups in Men 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            CC                                CT                                   TT 
 
Measure                           (n = 44)                         (n = 28)                           (n = 5) 
 
 
SNAP-2 BDL
a
        6.66 (4.61)       8.22 (4.64)          3.25 (2.87) 
 
BIS-11          61.89 (9.51)     63.61 (10.03)       68.80 (15.88) 
 
SCS                           128.16 (19.05)   118.68 (17.23)     113.20 (26.87) 
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Table 18 (continued). 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            CC                                CT                                   TT 
 
Measure                           (n = 44)                         (n = 28)                           (n = 5) 
 
 
SNAP-2 IMP
a
    4.84 (3.26)       6.33 (4.17)          4.25 (1.71) 
 
SNAP-2 DIS
a
  10.75 (5.67)     12.96 (5.63)        10.25 (2.50) 
 
LHA SDA      .23 (.74)         .29 (.85)            .20 (.45) 
 
SHI     2.16 (3.16)       2.75 (2.84)          1.20 (1.10) 
 
SNAP-2 SH
a
    1.27 (1.84)       1.59 (2.08)          1.00 (.82) 
 
SNAP-2 SP
a
                    .57 (1.02)         .70 (1.26)            .75 (.96) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne male CT participant and one male TT participant failed to complete the SNAP-2. 
 
Table 19 
 
Scores for SNCA rs356195 Allelic Groups in Men 
 
 
Measure   M (SD)    M (SD) 
 
 
      CC      CT/TT 
 
              (n = 44)    (n = 33) 
 
SNAP-2 BDL
a
                 6.66 (4.61)            7.58 (4.73) 
 
BIS-11                 61.89 (9.51)          64.39 (10.95) 
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Table 19 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
      CC      CT/TT 
 
              (n = 44)    (n = 33) 
 
SCS
 
                                 128.16 (19.05)*        117.85 (18.56)* 
 
SNAP-2 IMP
a 
           4.84 (3.26)            6.06 (3.98) 
 
SNAP-2 DIS
a
         10.75 (5.67)          12.61 (5.38) 
 
LHA SDA             .23 (.74)   .27 (.80) 
 
SHI            2.16 (3.16)            2.52 (2.69) 
 
SNAP-2 SH
a
            1.27 (1.84)            1.52 (1.96) 
 
SNAP-2 SP
a
               .57 (1.02)   .71 (1.22) 
 
 
      TT     CC/CT 
 
              (n = 5)    (n = 72) 
 
SNAP-2 BDL
a
                3.25 (2.87)            7.25 (4.65) 
 
BIS-11                68.80 (15.88)          62.56 (9.68) 
 
SCS
 
                                113.20 (26.87)        124.47 (18.83) 
 
SNAP-2 IMP
a
          4.25 (1.71)            5.41 (3.68) 
 
SNAP-2 DIS
a
        10.25 (2.50)          11.59 (5.72) 
 
LHA SDA            .20 (.45)   .25 (.78) 
 
SHI           1.20 (1.10)            2.39 (3.03) 
 
SNAP-2 SH
a
           1.00 (.82)            1.39 (1.92) 
 
 
55 
 
Table 19 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
      TT     CC/CT 
 
              (n = 5)    (n = 72) 
 
SNAP-2 SP
a
              .75 (.96)   .62 (1.11) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne male CT participant and one male TT participant failed to complete the SNAP-2. 
 
*different at p < .05 
 
Table 20 
 
Scores for SNCA rs356195 Genotypic Groups in Women 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            CC                                CT                                   TT 
 
Measure                           (n = 34)                         (n = 23)                          (n = 6) 
 
 
SNAP-2 BDL
a
        6.24 (3.61)
†
       7.04 (5.70)
†
       13.33 (4.59)
† 
 
BIS-11
b
          62.79 (10.66)     68.05 (14.22)       71.33 (11.45) 
 
SCS
b
                          124.91 (19.24)   124.05 (20.15)     109.67 (26.79) 
 
SNAP-2 IMP
a
    5.09 (3.13)       6.61 (4.94)          7.17 (4.83) 
 
SNAP-2 DIS
a
    8.73 (4.80)     10.65 (7.31)        13.67 (5.61) 
 
LHA SDA
b
      .62 (1.50)         .50 (1.23)          1.17 (1.47) 
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Table 20 (continued). 
 
 
             M (SD)   
           _______________________________________________________ 
 
                                            CC                                CT                                   TT 
 
Measure                           (n = 34)                         (n = 23)                          (n = 6) 
 
 
SHI
c
     2.50 (2.92)       3.19 (3.44)          4.50 (2.35) 
 
SNAP-2 SH
a
    1.15 (1.50)       1.43 (1.78)          3.50 (2.88) 
 
SNAP-2 SP
a
                    .70 (1.13)         .52 (1.16)          1.50 (1.87) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
 
aOne female CC participant failed to complete the SNAP-2. bOne female CT participant failed to complete the BIS-11, SCS, and LHA  
 
Self-Directed Aggression. cTwo female CT participants failed to complete the SHI. 
 
†Scores for female TT participants were nearly significantly higher than those for female CC and CT participants. 
 
Table 21 
 
Scores for SNCA rs356195 Allelic Groups in Women 
 
 
Measure   M (SD)    M (SD) 
 
 
      CC      CT/TT 
 
              (n = 34)    (n = 29) 
 
SNAP-2 BDL
a
                 6.24 (3.61)            8.34 (6.00) 
 
BIS-11
b
                 62.79 (10.66)
†
          68.75 (13.55)
† 
 
SCS
b 
                                124.91 (19.24)        120.96 (22.01) 
 
SNAP-2 IMP
a 
           5.09 (3.13)            6.72 (4.84) 
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Table 21 (continued). 
 
 
Measure   M (SD)    M (SD) 
 
 
      CC      CT/TT 
 
              (n = 34)    (n = 29) 
 
SNAP-2 DIS
a
           8.73 (4.80)          11.28 (7.01) 
 
LHA SDA
b
             .62 (1.50)   .64 (1.28) 
 
SHI
c
            2.50 (2.92)            3.48 (3.24) 
 
SNAP-2 SH
a
            1.15 (1.50)            1.86 (2.17) 
 
SNAP-2 SP
a
               .70 (1.13)   .72 (1.36) 
 
 
      TT     CC/CT 
 
              (n = 6)    (n = 57) 
 
SNAP-2 BDL
a
              13.33 (4.59)**            6.57 (4.55)** 
 
BIS-11
b
                71.33 (11.45)          64.86 (12.33) 
 
SCS
b 
                               109.67 (26.79)        124.57 (19.42) 
 
SNAP-2 IMP
a
          7.17 (4.83)            5.71 (4.00) 
 
SNAP-2 DIS
a
        13.67 (5.61)            9.52 (5.98) 
 
LHA SDA
b
          1.17 (1.47)   .57 (1.39) 
 
SHI
c
           4.50 (2.35)            2.76 (3.12) 
 
SNAP-2 SH
a
           3.50 (2.88)            1.27 (1.61) 
 
SNAP-2 SP
a
            1.50 (1.87)   .63 (1.14) 
 
 
Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide  
 
Proneness. 
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Table 21 (continued). 
 
 
aOne female CC participant failed to complete the SNAP-2. bOne female CT participant failed to complete the BIS-11, SCS, and LHA  
 
Self-Directed Aggression. cTwo female CT participants failed to complete the SHI. 
 
†nearly significantly different; **different at p < .01 
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 CHAPTER IV   
DISCUSSION 
COMT Rs4680 
 COMT rs4680 was the only SNP related to both categorically and continuously 
measured BPD: Heterozygotes (AG participants) displayed higher SNAP-2 Borderline 
scores (d = .39) and were nearly 7 times as likely to be diagnosed with clinical/subclinical 
BPD (  = .186, RR = 6.81) relative to homozygotes (AA/GG participants). Although the 
relationship between COMT zygosity and clinical/subclinical BPD was also significant in 
men (  = .254) but not in women (  = .105), effect sizes for men and women as well as 
for the total sample were comparable according to the effect size standards set forth by 
Cohen (1988/2009, pp. 223-225), in which = .1 is a “small” effect and = .3 is a 
“medium” effect. Additionally, Met homozygotes (AA participants) displayed lower 
SNAP-2 Borderline scores than heterozygotes (d = .47) and Val (G) carriers (d = .41). 
According to the effect size standards recommended by Cohen (1988/2009, pp. 25-26),  
d = .2 is a “small” effect; d = .5 is a “medium” effect; and d = .8 is a large effect. 
Therefore, all of the above-mentioned effects are rather small, albeit some are almost 
medium. Contrary to the current study, Tadic et al. (2009) found a higher percentage of 
COMT Met/Met (AA) genotype in Caucasian BPD patients compared to healthy 
participants, and Nemoda et al. (2010) failed to find a relationship between COMT 
rs4680 and BPD symptoms in a sample of Caucasian psychiatric inpatients or in an 
ethnically heterogeneous sample of at-risk young adults. It is noteworthy, however, that 
the current study was the first study to examine the relationship between COMT rs4680 
and BPD in an ethnically homogenous nonclinical sample. Thus, differences in study 
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design (i.e., case-control vs. cross-sectional) and sample selection (i.e., psychiatric/at-risk 
vs. nonclinical and also ethnically heterogeneous vs. ethnically homogeneous) may help 
to explain why results have been inconsistent across studies. 
 COMT rs4680 was related to impulse control only in women, which yielded 
several medium effects: Female Val homozygotes (GG participants) displayed lower 
SNAP-2 Disinhibition scores than female heterozygotes (d = .72) and Met (A) carriers  
(d = .68), and female heterozygotes also displayed higher BIS-11 (d = .45) and SNAP-2 
Disinhibition scores (d = .54) and lower SCS scores (indicative of greater impulsivity;  
d = .64) than female homozygotes. Most studies that have examined the relationship 
between COMT rs4680 and impulsivity or impulsivity-related traits have included a 
measure of novelty seeking, and none of those studies have been entirely consistent with 
the current results. Eight studies conducted with Caucasian, Asian, or Israeli participants 
failed to find a relationship between COMT rs4680 and novelty seeking (Benjamin et al., 
2000; Drabant et al., 2006; Hashimoto et al., 2007; Ishii et al., 2007; Kim et al., 2006; 
Light et al., 2007; Reuter & Hennig, 2005; Strobel et al., 2003), including those studies 
which separately analyzed men and women (Ishii et al., 2007; Kim et al., 2006; Reuter & 
Hennig, 2005), and four studies found patterns that were inconsistent with the current 
study, such as Met homozygotes displaying the highest novelty seeking scores 
(Demetrovics et al., 2010; Golimbet et al., 2007), Val homozygotes displaying higher 
novelty seeking scores than heterozygotes (Tsai et al., 2004), and Val homozygotes 
displaying lower novelty seeking scores than Met homozygotes in men but not in women 
(Chen et al., 2011). One study did find that Val homozygotes had lower novelty seeking 
scores than Met carriers, but the sample size was small (N = 37); and approximately 
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three-fourths of participants were men (Hosak et al., 2006). Similar to studies that have 
examined the relationship between COMT rs4680 and novelty seeking, one study failed 
to find a relationship between COMT rs4680 and sensation seeking in Koreans (Kang et 
al., 2010), and another study conducted with participants of German descent found that 
female Val homozygotes displayed significantly higher sensation seeking scores than 
female heterozygotes and female Met homozygotes (Lang et al., 2007). Of greatest 
relevance to the current study, no previous study has found a relationship between COMT 
rs4680 and trait impulsivity (Colzato et al., 2010; Forbes et al., 2009; Paloyelis et al., 
2010; Zalsman et al., 2008). However, none of those four studies separately analyzed 
males and females, and each study had further limitations or differences relative to the 
current study: Zalsman et al. (2008) administered an earlier version of the Barratt 
Impulsiveness Scale to currently depressed patients; Forbes et al. (2009) used a smaller 
sample (N = 86) that was somewhat ethnically heterogeneous (~90% white); Colzato et 
al. (2010) administered the Dickman Impulsivity Inventory and only compared Val 
homozygotes to Met carriers; and Paloyelis et al. (2010) administered the adolescent 
version of the BIS-11 to a smaller sample (N = 68) of males between the ages of 11 and 
20 (M = 15.42). Although the current study was not entirely consistent with any of the 
past studies that examined the relationship between COMT rs4680 and impulsivity or 
impulsivity-related traits, the current study was the first study to examine the relationship 
between COMT rs4680 and impulsivity in women. Thus, past studies that have searched 
for a relationship between COMT rs4680 and impulsivity may have been precluded from 
obtaining significant results because of their use of mixed-gender or male samples. 
Notably, the Val/Val genotype has been associated with higher levels of COMT activity, 
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which presumably leads to greater inactivation of DA and NE in the brain (Chen et al., 
2004; Lachman et al., 1996; Matsumoto et al., 2003). Consistent with female Val 
homozygotes displaying lower SNAP-2 Disinhibition scores in the current study, 
substances that increase DA or NE activity have been shown to increase impulsivity in 
patients with Parkinson’s disease and in healthy participants, respectively (Cools, Barker, 
Sahakian, & Robbins, 2003; Swann et al., 2005). 
 COMT rs4680 was related to self-harm in the total sample and in men, which 
yielded several small-to-medium effects: COMT Val homozygotes displayed lower LHA 
Self-Directed Aggression (d = .51) and SNAP-2 Self-Harm scores (d = .54) than 
heterozygotes and also lower LHA Self-Directed Aggression (d = .42) and SNAP-2 Self-
Harm scores (d = .47) than Met carriers, and heterozygotes further displayed higher 
SNAP-2 Self-Harm (d = .38) and SNAP-2 Suicide Proneness scores (d = .38) than 
homozygotes. In addition, male Met homozygotes displayed lower Suicide Proneness 
scores (d = .51) than male Val carriers. Contrary to the current study, a recent meta-
analysis (which included ten studies) and a simultaneously conducted study both failed to 
reveal a relationship between COMT rs4680 and suicidal behavior (Calati et al., 2011), 
and two other studies also were inconsistent with the current study: Massat et al. (2005) 
found a higher percentage of Val/Val genotype in bipolar disorder patients with a history 
of suicide attempt compared to patients who had never attempted suicide, and 
Silberschmidt and Sponheim (2008) failed to find a relationship between COMT rs4680 
and self-harm scores. However, all thirteen previous studies used samples of psychiatric 
patients or participants likely having a current psychiatric disorder (Baud et al., 2007; De 
Luca et al., 2006; De Luca, Tharmalingam, Sicard, & Kennedy, 2005; Liou, Tsai, Hong, 
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Wang, & Lai, 2001; Nolan et al., 2000; Ohara, Nagai, Suzuki, & Ohara, 1998; Ono et al., 
2004; Rujescu et al., 2003; Russ, Lachman, Kashdan, Saito, & Bajmakovic-Kacila, 2000; 
Zalsman et al., 2008). Although Ono et al. (2004) did not provide information concerning 
the psychiatric status of their participants, it can be safely assumed that the large majority 
of suicide completers in their study also had a psychiatric disorder given that past 
research has indicated that approximately 90% of suicide completers had a psychiatric 
disorder at the time of suicide (Mann, 2002). Furthermore, only three of the thirteen 
previous studies (Russ et al., 2000; Silberschmidt & Sponheim, 2008; Zalsman et al., 
2008) administered a continuous measure of self-harm or suicidal ideation instead of or 
in addition to ascertaining categorically-defined history of suicidal behavior (i.e., suicide 
or attempted suicide). In contrast to previous studies, in the current study healthy 
volunteers were administered a number of continuous self-harm measures representative 
of both suicidal behavior and less extreme forms of self-harm. For example, the LHA 
Self-Directed Aggression subscale consists of two items pertaining to frequency of past 
self-injurious behavior and suicide attempts; the SHI consists of 22 items pertaining to 
history of intentional self-harm, including suicidal and self-injurious behavior as well as 
self-destructive thoughts and behaviors; the SNAP-2 Self-Harm scale consists of 16 items 
pertaining to poor self-esteem, pessimistic thoughts, history of suicidal and self-injurious 
behavior, and thoughts of suicide and self-injury; and lastly the SNAP-2 Suicide 
Proneness subscale consists of 9 items pertaining to thoughts of suicide and self-injury 
and history of suicidal and self-injurious behavior (i.e., the SNAP-2 Self-Harm scale 
minus the items related to poor self-esteem and pessimistic thoughts). Therefore, 
differences in sample selection (i.e., clinical vs. nonclinical) and sensitivity of self-harm 
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measurement (i.e., measurement of suicidal behavior vs. continuous measurement of a 
wider range of self-harm) may help to explain the inconsistency across studies. 
 Although COMT is involved in the inactivation of DA and NE, COMT activity in 
the brain has mostly been related to its ability to modulate DA neurotransmission in the 
prefrontal cortex (Matsumoto et al., 2003), and genotypic variation in COMT rs4680 has 
been shown to influence COMT activity in the human brain, with Val homozygotes 
displaying greater COMT activity in the dorsolateral prefrontal cortex (DLPFC) than 
heterozygotes and Met homozygotes (Chen et al., 2004). Thus, in regard to the current 
findings in which Val homozygotes scored lower than heterozygotes or Met carriers, 
those findings may be explained (at least in part) by differences in DA neurotransmission 
in the DLPFC resulting from genotypically driven variation in COMT activity. 
Importantly, however, COMT activity may also indirectly affect the tonic and phasic 
release of DA in subcortical regions as a consequence of its aforementioned modulatory 
effect on cortical DA neurotransmission (Bilder, Volavka, Lachman, & Grace, 2004). 
Furthermore, COMT activity across various regions of the human brain as a function of 
COMT genotype has not been studied, and prior research involving other tissues (e.g., 
blood and liver) evidenced greater genotypically driven variation in COMT activity than 
that observed in the DLPFC, with distinctly low, medium, and high levels of COMT 
activity among Met/Met, Val/Met, and Val/Val genotypes, respectively (Lachman et al., 
1996). Therefore, a number of the current findings (including those in which Met 
homozygotes scored lower than heterozygotes or Val carriers) may be explained by 
differences in DA neurotransmission in some other brain region besides the DLPFC 
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(perhaps even in another prefrontal region) as a result of genotypically driven variation in 
COMT activity.  
Gender-specific results with COMT rs4680 may be explained by gender 
differences in COMT activity and dopaminergic function, both of which may be a 
consequence of the effects of estrogen. Men have displayed greater COMT activity than 
women (Chen et al., 2004; Xie, Ho, & Ramsden, 1999), which may be the result of 
higher estrogen levels in women leading to decreased COMT activity (Overpeck, Colson, 
Hohmann, Applestine, & Reilly, 1978; Xie et al., 1999). In addition, men and women 
have displayed differences in brain DA levels and receptor binding as well as differences 
in amphetamine-induced positive affect and regional DA release, which may be related to 
the effects of estrogen on dopaminergic function (Cantuti-Castelvetri et al., 2007; 
Haaxma et al., 2007; Munro et al., 2006; Riccardi et al., 2011, 2006). 
Admittedly, one set of findings in the current study presents greater difficulty in 
explaining: COMT heterozygotes frequently differed from homozygotes (i.e., Val and 
Met homozygotes combined). Previously mentioned research indicated that Val and Met 
homozygosity are at opposite ends in terms of level of COMT activity, and thus one 
would not expect heterozygotes to differ from homozygotes if self-reported differences 
are assumed to be the result of differences in DA neurotransmission in a particular brain 
region secondary to genotypically driven variation in COMT activity. However, this set 
of findings is consistent with the phenomenon known as molecular heterosis. Molecular 
heterosis occurs when individuals heterozygous for a genetic polymorphism display 
significantly more or less of an effect for a continuous or dichotomous trait than 
homozygotes, with positive heterosis indicating a greater effect and negative heterosis 
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indicating a lesser effect in heterozygotes (Comings & MacMurray, 2000). In the current 
study, results for COMT rs4680 were suggestive of positive heterosis for the following 
measures: SNAP-2 clinical/subclinical BPD diagnosis and SNAP-2 Borderline, Self-
Harm, and Suicide Proneness scores in the total sample, and BIS-11, SCS, and SNAP-2 
Disinhibition scores in women. Similar to the current study, one study reported a higher 
percentage of COMT heterozygosity (Val/Met genotype) in methamphetamine abusers 
who relapsed in comparison to abusers who remained abstinent after one year, suggestive 
of positive heterosis (Hosak, Horacek, Beranek, & Cermakova, 2007). In contrast to the 
current study, a recent meta-analysis of the relationship between COMT rs4680 and 
schizophrenia revealed a protective effect for heterozygosity, suggestive of negative 
heterosis (Costas et al., 2011). Negative COMT heterosis in relation to mental disorder or 
symptoms of mental disorder could be explained by an inverted U-shaped response 
curve, in which heterozygosity is associated with an optimal level of neurotransmitter 
function (Comings & MacMurray, 2000; Costas et al., 2011). Although positive COMT 
heterosis in relation to mental disorder or symptoms of mental disorder is not as readily 
explainable, one potential explanation is that COMT activity below a certain threshold 
may induce compensatory changes in the brain, and another potential explanation is that 
the trait in question may be excited or inhibited by multiple brain regions which are 
differentially affected by variation in COMT activity (Gogos et al., 1998). One final 
potential explanation is that COMT activity may also play a major role in modulating NE 
neurotransmission in the hippocampus (Matsumoto et al., 2003), which may interact with 
the effects of COMT activity on DA neurotransmission in the hippocampus and other 
parts of the brain. Consistent with this potential explanation and some other previously 
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mentioned ones, neuroimaging studies of BPD patients have revealed abnormalities in the 
frontolimbic network, including the hippocampus, DLPFC, and other prefrontal regions 
(Leichsenring, Leibing, Kruse, New, & Leweke, 2011; Schmahl & Bremner, 2006). 
GABRA2 Rs279871 
 GABRA2 rs279871 was related to BPD only in men, which yielded one medium 
effect: Male G homozygotes displayed lower SNAP-2 Borderline scores than male A-
allele carriers (d = .66). This is the first study to report a relationship between GABRA2 
and BPD symptoms. Interestingly, however, some previous studies have positively 
associated the A allele of GABRA2 rs279871 with conduct disorder symptoms (Dick, 
Bierut, et al., 2006), alcohol dependence (Dick, Bierut, et al., 2006; Edenberg et al., 2004; 
Philibert et al., 2009), and other drug dependence (Agrawal et al., 2006; Dick, Bierut, et 
al., 2006; Philibert et al., 2009), and another study using two large subsamples (n = 1105 
and n = 816) reported a higher percentage of antisocial personality disorder (ASPD) in 
participants with the AA genotype relative to G-carriers in both samples (Dick, Agrawal, 
et al., 2006). Because those studies did not separately analyze males and females, it is 
possible that the relationships they detected were more specific to males but were strong 
enough to yield significant results using mixed-gender samples, especially given that 
previous studies genotyped hundreds or even thousands of individuals. Based on current 
and past results, it appears that the A allele of GABRA2 rs279871 may be a risk factor 
for the development of personality- and substance-related psychopathology, particularly 
in males. 
 GABRA2 rs279871 was related to impulse control only in women, which yielded 
two medium effects: Female heterozygotes (AG participants) displayed higher BIS-11 
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scores than female GG participants (d = .60) and homozygotes (d = .56). Although no 
previous studies have examined the relationship between GABRA2 rs279871 and 
impulsivity, one study failed to reveal a relationship between GABRA2 rs279871 and 
novelty seeking (Dick, Agrawal, et al., 2006); however, that particular study only 
compared AA participants to G-allele carriers and did not separately analyze men and 
women. Consistent with the possibility that variation in GABRA2 influences the 
development of impulsivity, CSF GABA levels and cortical GABA concentrations have 
both been related to impulsivity in humans (Boy et al., 2011; Lee et al., 2009), and 
GABA-A agonists have been shown to increase impulsive responding in rodents (Le et 
al., 2008; Oliver et al., 2009; Thiebot et al., 1985) and impair inhibitory control in 
humans (Acheson et al., 2006; Deakin et al., 2004; Fillmore et al., 2001). Also, two other 
GABRA2 SNPs, GABRA2 rs279826 and GABRA2 rs279858, have been associated with 
impulsiveness scores, particularly in women (Villafuerte et al., 2011). Therefore, it is 
possible that variation in GABRA2 influences the development of impulsivity, 
particularly in women. 
 GABRA2 rs279871 was related to self-harm only in men, which yielded two 
small-to-medium effects: Male G homozygotes displayed lower SNAP-2 Suicide 
Proneness (d = .41) and SHI (d = .50) scores than A-allele carriers. Although no previous 
studies have examined the relationship between GABRA2 and self-harm, participants 
administered diazepam, a GABA-A agonist (Atack, 2005), have displayed increased self-
aggression (Berman et al., 2005), and personality-disordered individuals with a history of 
suicide attempts have displayed higher CSF GABA levels than personality-disordered 
individuals without a history of suicide attempts (Lee et al., 2009). Also as previously 
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mentioned, past studies have positively associated the A allele of GABRA2 rs279871 
with conduct disorder symptoms (Dick, Bierut, et al., 2006), alcohol dependence 
(Edenberg et al., 2004; Dick, Bierut, et al., 2006; Philibert et al., 2009), and other drug 
dependence (Agrawal et al., 2006; Dick, Bierut, et al., 2006; Philibert et al., 2009) and 
have associated the AA genotype with ASPD (Dick, Agrawal, et al., 2006). Thus, the A 
allele of GABRA2 rs279871 may be a risk factor for the development of personality- and 
substance-related psychopathology, including self-harm, again particularly in males. 
Although GABA-A receptor -2 subunits mostly have been related to anxiety 
(Dixon et al., 2008; Lehner et al., 2010; Low et al., 2000), they may be involved in other 
emotional responses and emotionally driven behaviors, such as depression (Vollenweider 
et al., 2011) and impulsive actions motivated by negative affective states (Villafuerte et 
al., 2011). As stated previously, GABA-A receptor -2 subunits are distributed 
throughout brain regions involved in the regulation of emotion (e.g., prefrontal cortex, 
amygdala, and hippocampus) (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al., 
2010; Low et al., 2000; Tian et al., 2005), and neuroimaging studies of BPD patients have 
revealed abnormalities in the frontolimbic network, including the prefrontal cortex, 
amygdala, and hippocampus (Leichsenring et al., 2011; Schmahl & Bremner, 2006). 
According to the DSM-IV-TR, BPD is characterized in part by mood reactivity (e.g., 
intense intermittent states of depression, anxiety, or irritability) and impairments in 
impulse control, possibly including substance abuse (American Psychiatric Association, 
2000). Given all of the preceding information, it is reasonable to suspect that GABRA2 
may influence a diversity of emotional responses and emotionally driven behaviors and 
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by extension may influence the development of BPD and related traits and behaviors, 
such as impulsivity and self-harm. 
 Intriguingly, all of the current findings in relation to GABRA2 rs279871 were 
gender-specific. Such findings may be explained by gender differences in the levels of 
steroid hormones (e.g., progesterone and testosterone) and neurosteroids as well as by 
gender differences in the effects of neurosteroids and in the structure of brain regions 
containing GABA-A receptor -2 subunits. Neurosteroids, such as allopregnanolone (a 
neuroactive metabolite of progesterone), androstanediol (a neuroactive metabolite of 
testosterone), dehydroepiandrosterone (DHEA), and its sulfated metabolite, DHEA 
sulfate (DHEAS), can act as positive or negative allosteric modulators of GABA-A 
receptor function (Engel & Grant, 2001; Reddy, 2010). Furthermore, allopregnanolone, 
DHEA, and DHEAS can also enhance or attenuate GABA-A receptor-mediated 
inhibition of 5-HT neuronal activity (Gartside, Griffith, Kaura, & Ingram, 2010; Kaura, 
Ingram, Gartside, Young, & Judge, 2007). In regard to gender differences, circulating 
levels of progesterone and allopregnanolone have been shown to be higher in women 
during the luteal phase than in men (Genazzani et al., 1998; Overpeck et al., 1978); blood 
levels of testosterone and androstanediol have been shown to be higher in men than in 
women (Overpeck et al., 1978; Strickland & Apland, 1977; Wudy, Wachter, Homoki, & 
Teller, 1996); blood-serum concentrations of DHEA have been shown to be higher in 
women than in men (Genazzani et al., 1998); and serum levels of DHEAS have been 
shown to be higher in males in comparison to females across all age groups between the 
ages of 17 and 69 years, with the largest difference in DHEAS levels occurring between 
the ages of 20 and 29 years (Young, Skibinski, Mason, & James, 1999). Also, one study 
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revealed sex differences in the anxiogenic effects of acute exposure to progesterone and 
allopregnanolone in rats (Gulinello & Smith, 2003), raising the possibility that gender 
differences in the effects of neurosteroids may occur in humans. Finally, neuroimaging 
has revealed gender differences (relative to cerebrum size) in the sizes of the amygdala 
and prefrontal regions (Goldstein et al., 2001), which are brain regions containing 
GABA-A receptor -2 subunits (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al., 
2010; Low et al., 2000; Tian et al., 2005).  
 In the current study, BIS-11 results for GABRA2 rs279871 were suggestive of 
positive heterosis in women. Perhaps related to impulsivity, one previous GABRA2 
rs279871 study reported a higher proportion of AG genotype and a lower proportion of 
GG genotype in polysubstance abusers compared to control participants (Drgon, 
D’Addario, & Uhl, 2006). Similar to one aforementioned potential explanation for 
positive COMT heterosis in relation to symptoms of mental disorder, positive GABRA2 
heterosis  in relation to impulsivity may be explained by impulsive behavior being 
excited or inhibited by multiple brain regions which are differentially affected by 
genetically influenced variation in GABA-A -2 subunit receptor function. 
SNCA Rs356195 
 SNCA rs356195 was related to BPD only in women, which yielded three large 
effects: Female T homozygotes displayed higher SNAP-2 Borderline scores than female 
C homozygotes (d = 1.89), heterozygotes (d = 1.14), and C-allele carriers (d = 1.48). This 
is the first study to report a relationship between SNCA and BPD symptoms. SNCA 
rs356195 was also related to impulsivity across all four measures of impulse control, 
which yielded several small-to-medium effects: T-allele carriers displayed lower SCS 
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scores (indicative of greater impulsivity; d = .38) and higher BIS-11 (d = .37), SNAP-2 
Impulsivity (d = .38), and SNAP-2 Disinhibition scores (d = .36) than C homozygotes, 
and T homozygotes displayed higher BIS-11 scores than C-allele carriers (d = .60). In 
addition, gender-specific analyses revealed higher BIS-11 scores in female T-allele 
carriers in comparison to female C homozygotes (d = .50) and lower SCS scores 
(indicative of greater impulsivity) in male T-allele carriers in comparison to male C 
homozygotes (d = .55). Although no previous studies have examined the relationship 
between SNCA and impulsivity or impulsivity-related traits, -synuclein expression in 
the striatum has been shown to influence stimulant-induced locomotion in rodents 
(Abeliovich et al., 2000; Boyer & Dreyer, 2007), which is a behavior associated with 
impulsive responding in rats  (Dellu-Hagedorn, 2006). Of potential relevance to the 
current findings, the C allele of SNCA rs356195 has been negatively associated with 
history of alcohol craving (Foroud et al., 2007), and blood -synuclein levels have been 
positively correlated with alcohol and cocaine craving scores (Bonsch et al., 2004; Mash 
et al., 2008). Notably, alcohol-related psychopathology has been related both to 
dimensionally and diagnostically measured BPD: More specifically, BPD symptoms have 
been positively correlated with alcohol use disorder in a nonclinical sample of 395 young 
adults (Trull et al., 2004), and BPD is estimated to be the most commonly diagnosed 
lifetime personality disorder among individuals with a 12-month alcohol use disorder in 
the general population (Grant et al., 2008, 2004). Based on past and present findings, it is 
tempting to speculate that the C allele of SNCA 356195 may be a protective factor 
against the development of impulsivity, which in turn may serve as a protective factor 
73 
 
against the development of disorders involving poor impulse control, such as BPD and 
substance-related disorders.  
SNCA rs356195 was not significantly related to self-harm in the total sample or 
by gender. One possible explanation is that there is no relationship between SNCA 
rs356195 and self-harm. However, another possibility is that the current study lacked 
adequate power to detect a relationship between SNCA rs356195 and self-harm. A visual 
examination of Tables 16 and 20 appears to support the latter possibility: T homozygotes 
displayed the highest scores across all four self-harm measures in the total sample and 
particularly in women. Greater self-harm in female T homozygotes also would have been 
consistent with the current study’s finding of greater BPD symptoms in female T 
homozygotes. Thus, it would be premature to conclude that SNCA rs356195 is probably 
not related to self-harm, especially given that this is the first study to examine the 
relationship between SNCA and self-harm. 
Although -synuclein may modulate DA, 5-HT, and NE transporter activity 
(Venda et al., 2010; Wersinger, Jeannotte, et al., 2006; Wersinger, Rusnak, et al., 2006; 
however, also see Senior et al., 2008), it most clearly has been shown to reduce DA 
biosynthesis and release (Venda et al., 2010). Consistent with a role for -synuclein (and 
thus SNCA) in the etiology of BPD and related traits and behaviors, DA blockers have 
been shown to decrease impulsivity and suicidal behavior in patients with BPD (Friedel, 
2004), and L-DOPA (which increases DA activity) has been shown to increase 
impulsivity in patients with Parkinson’s disease (Cools et al., 2003). Moreover, DA 
receptors are found in the prefrontal cortex, amygdala, and hippocampus (Matsumoto et 
al., 2003; Wise, 2009), which are all brain regions where -synuclein is highly expressed 
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(Clayton & George, 1998; Jakes, Spillantini, & Goedert, 1994; Venda et al., 2010; 
Ziolkowska et al., 2005) and where abnormalities have been detected in BPD patients 
(Leichsenring et al., 2011; Schmahl & Bremner, 2006). Therefore, SNCA may influence 
the development of BPD and related traits and behaviors via the effects of -synuclein on 
DA biosynthesis and release in the prefrontal cortex, amygdala, and/or hippocampus. 
In regard to gender-specific results with SNCA rs356195, such findings may be 
explained by gender differences in the DA and -synuclein systems. As stated 
previously, men and women have displayed differences in brain DA levels and receptor 
binding as well as differences in amphetamine-induced positive affect and regional DA 
release, which may be related to the effects of estrogen on dopaminergic function 
(Cantuti-Castelvetri et al., 2007; Haaxma et al., 2007; Munro et al., 2006; Riccardi et al., 
2011, 2006). Lewy bodies, which are intracellular inclusions primarily found in brain 
neurons and mostly composed of -synuclein, are characteristic of neurodegenerative 
disorders such as Parkinson’s disease and dementia with Lewy bodies (Clayton & 
George, 1998; Nelson et al., 2010; Venda et al., 2010; Ziolkowska et al., 2005), and men 
are at greater risk of developing Parkinson’s disease and neocortical and limbic Lewy 
bodies and have displayed greater -synuclein expression in dopaminergic neurons 
(Cantuti-Castelvetri et al., 2007; Haaxma et al., 2007; Nelson et al., 2010). 
Limitations 
 In a nationally representative sample, the majority of individuals diagnosed with 
lifetime BPD also had at least one 12-month substance use, mood, or anxiety disorder 
(Grant et al., 2008), and in large nonclinical samples BPD symptoms or features have 
been positively correlated with anxiety, mood, and alcohol and drug use disorders (Trull, 
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1995; Trull et al., 2004). Thus, one limitation is that, as part of a larger research project, 
the current study discouraged recent drug use and also excluded potential problem 
drinkers and individuals who reported experiencing a lifetime bipolar disorder or a recent 
depressive or anxiety disorder, which may have made it more difficult to detect genetic 
associations as a result of restricting the number of individuals diagnosed with BPD as 
well as the range of BPD, impulse control, and self-harm scores. For example, although 
one SNP (COMT rs4680) was associated with a diagnosis of clinical/subclinical BPD, 
the current study failed to detect an association between any of the SNPs and a diagnosis 
of clinical BPD; however, only 2.9% of participants (n = 4) received a diagnosis of 
clinical BPD in the total sample (83.3% of which was composed of individuals between 
the ages of 21 and 29). In comparison, 9.3% of individuals between the ages of 20 and 29 
in a nationally representative sample received a diagnosis of lifetime BPD (Grant et al., 
2008). Nevertheless, the use of a nonclinical sample free of a number of psychiatric and 
medical disorders and current exposure to psychiatric medications is also a strength 
because it removes several factors that may confound genetic associations with BPD. 
Another limitation of the current study is its sample size. The effect size of any single 
SNP tends to be rather small, and detecting such an effect may require a sample size in 
the hundreds. In the current study (which used a total sample of 140 participants), only 
effect sizes that were approximately mid-range between small and medium or larger were 
significant in the total sample, and only effect sizes that were about medium-to-large 
were significant when analyzed by gender. Sample size also would not have been 
sufficient to search for SNP interactions because cell sizes for several genotypic pairings 
in the total sample would have been less than 5 (with some cell sizes as small as 1). 
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Another limitation of the current study is its reliance on self-report instruments. It would 
have been interesting and perhaps more compelling if self-report measures of impulse 
control and self-harm had been supplemented with behavioral measures of impulsivity 
and self-aggression. Another limitation is that the current study only included individuals 
who self-identified as Caucasian. Although this practice was employed in order to limit 
the potentially confounding effects of population stratification, it also limits the ability to 
generalize current results beyond that of Caucasians. One final limitation of the current 
study, which is a limitation common to genetic association studies, is that genetic 
variation in particular SNPs cannot be inferred to be causative but only suggestive of a 
causative role for the genes in which those SNPs partially represent. COMT rs4680 has 
been shown to be a functional SNP (i.e., has been shown to influence physiological 
differences in the body), but it is still possible that genotypes or alleles of all three SNPs 
are not independent of genotypes or alleles of other SNPs (i.e., that all three SNPs are in 
linkage disequilibrium with other SNPs) and that it is those other SNPs which play a 
more direct role in the development of BPD and related traits and behaviors. 
Future Directions 
 In addition to attempting to replicate current results, future studies should search 
for associations between the current SNPs and behavioral measures of impulsivity and 
self-aggression. Future research should also attempt to expand the current results by 
examining SNP-SNP and SNP-environment interactions in relation to BPD, impulse 
control, and self-harm. Specifically related to COMT rs4680, it may be fruitful to 
genotype and administer behavioral measures of impulsivity and self-aggression to 
individuals acutely exposed to placebo or a centrally active COMT inhibitor, such as 
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tolcapone (Apud et al., 2007). In relation to SNCA rs356195 (and other SNPs of SNCA), 
it may be useful to measure -synuclein expression (i.e., protein or mRNA levels) in the 
blood combined with genotyping and the administration of tests or tasks. Given the 
possible role of GABA-A receptor -2 subunits in the regulation of emotion, the 
literature is in need of studies involving GABRA2 genotyping and measurement of mood 
and anxiety disorder symptoms. Because results for all three of the current SNPs may 
have been affected by steroid hormones and neurosteroids, it may also be beneficial to 
record the temporal proximity to menstruation in women (as a proxy measure of 
progesterone, allopregnanolone, and estrogen) or to measure the levels of circulating 
steroids in participants in addition to genotyping and administering behavioral measures 
of impulsivity and self-aggression. Finally, the addition of functional neuroimaging 
(particularly of the frontolimbic network) to future genetic association studies would be 
helpful in increasing knowledge of gene-brain-behavior relationships. 
Summary 
 COMT rs4680 was the only SNP related to both categorically and continuously 
measured BPD as well as to impulse control and self-harm scores. However, COMT 
heterozygotes often differing from the combined group of homozygotes (suggestive of 
heterosis) presents difficulty in explaining, although some potential explanations were 
proposed. In regard to the other SNPs, GABRA2 rs279871 was related to BPD, impulse 
control, and self-harm scores, whereas SNCA rs356195 was only related to the former 
two. Results in relation to GABRA2 rs279871 were entirely gender-specific, and COMT 
rs4680 and SNCA rs356195 also yielded some gender-specific results. Gender-specific 
results with COMT rs4680 may be explained by gender differences in COMT activity 
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and dopaminergic function; gender-specific results with GABRA2 rs279871 may be 
explained by gender differences in the levels of steroid hormones and neurosteroids as 
well as by gender differences in the effects of neurosteroids and in the structure of brain 
regions containing GABA-A receptor -2 subunits; and gender-specific results with 
SNCA rs356195 may be explained by gender differences in the DA and -synuclein 
systems. In conclusion, it appears that COMT, GABRA2, and SNCA may influence the 
development of BPD and related traits and behaviors. 
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APPENDIX A 
IRB FORM 
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APPENDIX B 
BARRATT IMPULSIVENESS SCALE, VERSION 11 (BIS-11) 
Instructions: For each item, please select the number corresponding to how often the 
statement is true of you.  
 
1 = Rarely/Never  
2 = Occassionally  
3 = Often  
4 = Almost Always/Always   
 
1. I plan tasks carefully 
 
1      2      3      4    
 
2. I do things without thinking  
 
1      2      3      4    
 
3. I make-up my mind quickly  
 
1      2      3      4    
 
4. I am happy go lucky  
 
1      2      3      4    
 
5. I don’t “pay attention”  
 
1      2      3      4    
 
6. I have “racing” thoughts  
 
1      2      3      4    
 
7. I plan trips well ahead of time  
 
1      2      3      4    
 
8. I am self-controlled  
 
1      2      3      4    
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9. I concentrate easily  
 
1      2      3      4    
 
10. I save regularly  
 
1      2      3      4    
 
11. I “squirm” at plays or lectures  
 
1      2      3      4    
 
12. I am a careful thinker  
 
1      2      3      4    
 
13. I plan for job security  
 
1      2      3      4    
 
14. I say things without thinking  
 
1      2      3      4    
 
15. I like to think about complex problems  
 
1      2      3      4    
 
16. I change jobs  
 
1      2      3      4    
 
17. I act “on impulse”  
 
1      2      3      4    
 
18. I get easily bored when solving thought problems  
 
1      2      3      4    
 
19. I act on the spur of the moment  
 
1      2      3      4    
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20. I am a steady thinker  
 
1      2      3      4    
 
21. I change residences  
 
1      2      3      4    
 
22. I buy things on impulse  
 
1      2      3      4    
 
23. I can only think about one problem at a time  
 
1      2      3      4    
 
24. I change hobbies  
 
1      2      3      4    
 
25. I spend or charge more than I earn  
 
1      2      3      4    
 
26. I often have extraneous thoughts when thinking  
 
1      2      3      4    
 
27. I am more interested in the present than in the future  
 
1      2      3      4    
 
28. I am restless at theaters or lectures 
 
1      2      3      4    
 
29. I like puzzles  
 
1      2      3      4    
 
30. I am future oriented  
 
1      2      3      4    
 
 
83 
 
APPENDIX C 
LIFE HISTORY OF AGGRESSION SELF-DIRECTED AGGRESSION SUBSCALE 
(LHA SELF-DIRECTED AGGRESSION) 
Instructions: Rate yourself on each of the following items using the rating system below. 
Only rate actual behavior be it verbal and/or physical. Do not include in your ratings 
thoughts not followed by any action or fantasies. For these questions it is important to 
rate any events that have occurred over your lifetime (including your years as a teenager 
and a young adult). 
 
0 = Never Happened   
1 = Only Happened Once   
2 = Happened a Couple of Times (2-3)   
3 = Happened Several Times (4-9)  
4 = Happened Many Times (10+)  
5 =  Happened So Many Times I Couldn't Give a Number      
  
How Many Times Would You Say You Did the Following Things Over the Course of 
Your Life to DATE? 
 
1. Deliberately tried to physically hurt yourself in anger or desperation.  
 
0                 1                  2                  3                  4                  5    
 
2. Deliberately tried to end your life or kill yourself in anger or desperation. 
 
0                 1                  2                  3                  4                  5    
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APPENDIX D 
SELF-CONTROL SCALE (SCS) 
Instructions: Using the following scale, please indicate how much each of the following 
statements reflects how you typically are. 
 
1 = Not Like Me At All     
2    
3   
4       
5 = Very Much Like Me  
 
1. I have a hard time breaking bad habits. 
 
1  2  3  4  5   
 
2. I am lazy. 
 
1  2  3  4  5   
 
3. I say inappropriate things. 
 
1  2  3  4  5   
 
4. I never allow myself to lose control. 
 
1  2  3  4  5   
 
5. I do certain things that are bad for me, if they are fun. 
 
1  2  3  4  5   
 
6. People can count on me to keep on schedule. 
 
1  2  3  4  5   
 
7. Getting up in the morning is hard for me. 
 
1  2  3  4  5   
 
8. I have trouble saying no. 
 
1  2  3  4  5   
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9. I change my mind fairly often. 
 
1  2  3  4  5   
 
10. I blurt out whatever is on my mind. 
 
1  2  3  4  5   
 
11. People would describe me as impulsive 
 
1  2  3  4  5   
 
12. I refuse things that are bad for me. 
 
1  2  3  4  5   
 
13. I spend too much money. 
 
1  2  3  4  5   
 
14. I keep everything neat. 
 
1  2  3  4  5   
 
15. I am self-indulgent at times. 
 
1  2  3  4  5   
 
16. I wish I had more self-discipline. 
 
1  2  3  4  5   
 
17. I am good at resisting temptation. 
 
1  2  3  4  5   
 
18. I get carried away by my feelings. 
 
1  2  3  4  5   
 
19. I do many things on the spur of the moment. 
 
1  2  3  4  5   
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20. I don't keep secrets very well. 
 
1  2  3  4  5   
 
21. People would say that I have iron self-discipline. 
 
1  2  3  4  5   
 
22. I have worked or studied all night at the last minute. 
 
1  2  3  4  5   
 
23. I'm not easily discouraged. 
 
1  2  3  4  5   
 
24. I'd be better off if I stopped to think before acting. 
 
1  2  3  4  5   
 
25. I engage in healthy practices. 
 
1  2  3  4  5   
 
26. I eat healthy foods. 
 
1  2  3  4  5   
 
27. Pleasure and fun sometimes keep me from getting work done. 
 
1  2  3  4  5   
 
28. I have trouble concentrating. 
 
1  2  3  4  5   
 
29. I am able to work effectively toward long-term goals. 
 
1  2  3  4  5   
 
30. Sometimes I can't stop myself from doing something, even if I know it is wrong. 
 
1  2  3  4  5   
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31. I often act without thinking through all the alternatives. 
 
1  2  3  4  5   
 
32. I lose my temper too easily. 
 
1  2  3  4  5   
 
33. I often interrupt people. 
 
1  2  3  4  5   
 
34. I sometimes drink or use drugs to excess. 
 
1  2  3  4  5   
 
35. I am always on time. 
 
1  2  3  4  5   
 
36. I am reliable. 
 
1  2  3  4  5   
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